<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cell Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">Front Cell Neurosci</journal-id><journal-id journal-id-type="pmc-domain-id">639</journal-id><journal-id journal-id-type="pmc-domain">frontcellneuro</journal-id><journal-id journal-id-type="publisher-id">Front. Cell. Neurosci.</journal-id><journal-title-group><journal-title>Frontiers in Cellular Neuroscience</journal-title></journal-title-group><issn pub-type="epub">1662-5102</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11617155</article-id><article-id pub-id-type="pmcid-ver">PMC11617155.1</article-id><article-id pub-id-type="pmcaid">11617155</article-id><article-id pub-id-type="pmcaiid">11617155</article-id><article-id pub-id-type="pmid">39640234</article-id><article-id pub-id-type="doi">10.3389/fncel.2024.1502473</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Cellular Neuroscience</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Bridging the gap of vision restoration</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Carleton</surname><given-names initials="M">Maya</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1998766/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Oesch</surname><given-names initials="NW">Nicholas W.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1998691/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Psychology, University of California San Diego</institution>, <addr-line>La Jolla, CA</addr-line>, <country>United States</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Ophthalmology, University of California San Diego</institution>, <addr-line>La Jolla, CA</addr-line>, <country>United States</country></aff><aff id="aff3"><sup>3</sup><institution>Neuroscience Graduate Program, University of California San Diego</institution>, <addr-line>La Jolla, CA</addr-line>, <country>United States</country></aff><author-notes><fn fn-type="edited-by" id="fn0001"><p>Edited by: Gunnar P. H. Dietz, University Medical Center G&#246;ttingen, Germany</p></fn><fn fn-type="edited-by" id="fn0002"><p>Reviewed by: John O&#8217;Brien, University of Houston, United States</p><p>Gladys Y. P. Ko, Texas A and M University, United States</p></fn><corresp id="c001">*Correspondence: Nicholas W. Oesch, <email>noesch@ucsd.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>18</volume><issue-id pub-id-type="pmc-issue-id">454014</issue-id><elocation-id>1502473</elocation-id><history><date date-type="received"><day>26</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>06</day><month>11</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>05</day><month>12</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-12-06 09:25:45.897"><day>06</day><month>12</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2024 Carleton and Oesch.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Carleton and Oesch</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fncel-18-1502473.pdf"/><abstract><p>Retinitis pigmentosa (RP) and Age-Related Macular Degeneration (AMD) are similar in that both result in photoreceptor degeneration leading to permanent progressive vision loss. This affords the possibility of implementing vision restoration techniques, where light signaling is restored to spared retinal circuitry to recreate vision. There are far more AMD patients (Wong et al., 2014), yet more resources have been put towards researching and developing vision restoration strategies for RP despite it rarity, because of the tractability of RP disease models. The hope is that these therapies will extend to the AMD population, however, many questions remain about how the implementation of prosthetic or optogenetic vision restoration technologies will translate between RP and AMD patients. In this review, we discuss the difference and similarities of RP and AMD with a focus on aspects expected to impact vision restoration strategies, and we identify key gaps in knowledge needed to further improve vision restoration technologies for a broad patient population.</p></abstract><kwd-group><kwd>vision restoration</kwd><kwd>retinal degeneration</kwd><kwd>age related macular degeneration</kwd><kwd>retinitis pigmentosa</kwd><kwd>retinal prosthesis</kwd><kwd>retina</kwd><kwd>optogenetics</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by NIH EY029259 to NWO.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="1"/><equation-count count="0"/><ref-count count="149"/><page-count count="14"/><word-count count="12878"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Cellular Neuropathology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1"><label>1</label><title>Introduction</title><p>The retina is a part of the central nervous system responsible for the first steps in vision. It consists of light sensitive cells, called photoreceptors, interneurons for processing visual information and retinal ganglion cells whose axons make up the optic nerve and send visual signals to the brain (<xref rid="fig1" ref-type="fig">Figure 1A</xref>). Retinal Degenerative Diseases (RDD) are the leading cause of blindness in humans, with Age-Related Macular Degeneration (AMD) being the most common. AMD currently affects 196 million people throughout the world, with the prevalence expected to increase as the global population ages (<xref rid="ref135" ref-type="bibr">Wong et al., 2014</xref>; <xref rid="ref10" ref-type="bibr">Bourne et al., 2017</xref>). In contrast, Retinitis Pigmentosa (RP) is a RDD with a smaller clinical population of around 2 million globally, however, it is still the most prevalent cause of inherited blindness (<xref rid="ref35" ref-type="bibr">Garip and Kamal, 2019</xref>). Both diseases ultimately result in the loss of photoreceptors leading to local or global blindness, and no cure exists for the vast majority of cases.</p><fig position="float" id="fig1" orientation="portrait"><label>Figure 1</label><caption><p>Structure of the retina and vision restoration strategies after photoreceptor degeneration. <bold>(A)</bold> The structure of the healthy retina is laminated into distinct layers. After photoreceptor loss due to RP or AMD, vision restoration strategies can be implemented. <bold>(B)</bold> Optoelectronic prosthetics utilize a camera mounted to external hardware and a processor which amplifies natural light and projects Near Infrared light (NIR) into the eye onto a photovoltaic array to generate stimulating current through a microelectrode array. <bold>(C)</bold> Optogenetic restoration uses a viral vector to introduce a light sensitive ion channel targeted to bipolar or ganglion cells. Utilizing a similar external setup to photovoltaic optoelectronics, light from the environment is amplified to obtain sufficient activation of the light sensitive molecule. Created with <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.biorender.com" ext-link-type="uri">www.biorender.com</ext-link>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fncel-18-1502473-g001.jpg"/></fig><p>One strategy to restore vision in these patients is to replace the light sensing photoreceptor vision with an artificial phototransducing technology. Currently, there are two main strategies, optoelectronic visual prostheses, and optogenetics. Optoelectronic prosthesis utilizes implantable semiconductor based light sensors coupled to stimulating microelectrodes to excite neurons downstream of the photoreceptors. These can be placed between the pigment epithelium and remaining bipolar cells (subretinal) (<xref rid="ref86" ref-type="bibr">Muqit et al., 2024</xref>), implanted into the suprachoroidal space (<xref rid="ref58" ref-type="bibr">Karapanos et al., 2021</xref>) or placed above retinal ganglion cells (epiretinal) (<xref rid="ref77" ref-type="bibr">Luo and da Cruz, 2016</xref>) (<xref rid="fig1" ref-type="fig">Figure 1B</xref>). In contrast, the optogenetic approach uses gene therapy vectors to introduce non-native light sensitive proteins into spared cells of the retina bipolar cells (<xref rid="ref136" ref-type="bibr">Wood et al., 2023</xref>), or ganglion cells (<xref rid="ref80" ref-type="bibr">McGregor et al., 2020</xref>) (<xref rid="fig1" ref-type="fig">Figure 1C</xref>). Both technologies are being used in clinical trials, but no one therapy is targeting both diseases, and currently no vision restoration technology is available in the marketplace.</p><p>Vision restoration strategies have primarily targeted RP despite the smaller patient population, because late-stage RP patients with bare or no light perception have little risk for worsening vision. This strategy limits the accessibility of vision restoration therapies to the relatively small population of patients with late-stage RP (<xref rid="ref130" ref-type="bibr">Walsh et al., 2018</xref>). The common hope is that if a vision restoration technology can show safety and efficacy in an RP patient population, it may be translated to AMD patients in the future, unlocking a much larger patient population. However, the pre-clinical work, remains incomplete.</p><p>Although reintroducing light sensitivity to the retina appears generally feasible, a major challenge is that spared retina can undergo structural and functional plasticity following the degeneration of photoreceptors, which can affect downstream signaling. How inner retinal changes in RP and AMD are similar or different is still unknown Therefore, understanding the degree to which these changes impact the restoration of visual signals will crucially influence the degree of success in vision restoration. Here we provide a review of RP and AMD, to understand the functional and anatomical changes in both diseases. Given that most preclinical vision restoration work is done in the context of RP, while the larger patient population lies in AMD, the knowledge of where the RP literature can be leveraged to aid in AMD, and where the diseases differ will be paramount to bringing vision restoration strategies to the broader RDD patient population. Here, we highlight current gaps in knowledge that are important for the implementation of high-fidelity vision restoration in patients with both RP and AMD.</p></sec><sec id="sec2"><label>2</label><title>Retinitis pigmentosa</title><sec id="sec3"><label>2.1</label><title>Etiology</title><p>Retinitis Pigmentosa is comprised of a class of heterogeneous gene mutations and phenotypes (<xref rid="ref128" ref-type="bibr">Van Soest et al., 1999</xref>). Mutations can be classified as non-syndromic, affecting the retina in isolation, or syndromic in which retinal degeneration coincides with other disease processes that occur outside the eye (<xref rid="ref41" ref-type="bibr">Hamel, 2006</xref>). The most notable syndromic diseases are Usher syndrome and Bardet-Biedl syndrome, but there are approximately thirty syndromes coincident with RP (<xref rid="ref101" ref-type="bibr">Phelan and Bok, 2000</xref>).</p><p>Non-syndromic retinitis pigmentosa is a class of inherited retinal dystrophies that present without other systematic abnormalities (<xref rid="ref104" ref-type="bibr">Pierrottet et al., 2014</xref>). Inherited non-syndromic RPs are composed of autosomal dominant (15&#8211;20%), autosomal recessive (5&#8211;20%), X-linked (5&#8211;15%), and a vast majority of unknown genetic patterns (40&#8211;50%) (<xref rid="ref28" ref-type="bibr">Fahim et al., 1993</xref>). Eighty-four gene mutations have been identified so far, affecting a wide range of biological functions, which ultimately result in the death of rod photoreceptors. Principal genes affect the visual transduction cascade, visual cycle, and ciliary function and transport within rod photoreceptors (<xref rid="ref129" ref-type="bibr">Verbakel et al., 2018</xref>).</p><p><xref rid="fig2" ref-type="fig">Figure 2</xref> displays some genes in the visual transduction cascade and photopigment cycle that when disrupted result in RP. Almost every step in the phototransduction cascade and cycle when disrupted could potentially result in rod death and the development of RP. There are four dominant pathways to apoptosis in rods; mutations that create endoplasmic reticulum (ER) stress, excitotoxic levels of cGMP, excitotoxic levels of intracellular calcium, and continuous phototransduction (<xref rid="ref69" ref-type="bibr">Koenekoop, 2011</xref>; <xref rid="ref90" ref-type="bibr">Newton and Megaw, 2020</xref>). <italic toggle="yes">RHO</italic> mutations are the most common mutations in RP and many affect protein folding. Excess accumulation of misfolded proteins in the ER can result in stress and ultimately the activation of apoptotic pathways via caspases (<xref rid="ref22" ref-type="bibr">Comitato et al., 2020</xref>). Gene mutations such as those to the phosphodiesterase subunits results in excitotoxic levels of cGMP as they are no longer hydrolyzed to 5&#8217; GMP and increases intracellular calcium (<xref rid="ref6" ref-type="bibr">Barabas et al., 2010</xref>). Finally, mutations in genes such as <italic toggle="yes">RPE65</italic> and <italic toggle="yes">GNAT1</italic> result in the continuous activation of the phototransduction cascade (<xref rid="ref42" ref-type="bibr">Hao et al., 2002</xref>), recruiting similar apoptotic pathways to those observed in light damage.</p><fig position="float" id="fig2" orientation="portrait"><label>Figure 2</label><caption><p>Genes of the visual transduction and visual cycle known to cause RP. The phototransduction cascade and visual cycle are a tightly regulated series of steps requiring the correct function of many proteins. Mutations in the genes encoding these proteins can lead to apoptosis via endoplasmic reticulum stress, excitotoxic levels of cGMP, excitotoxic levels of intracellular calcium, and continuous phototransduction. Created with <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.biorender.com" ext-link-type="uri">www.biorender.com</ext-link>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fncel-18-1502473-g002.jpg"/></fig><p>Ciliopathies, which affect ciliogenesis and ciliary protein trafficking, can have detrimental effects on many bodily organs including photoreceptors which are specialized sensory cilia. Rod-cone atrophy in both Usher Syndrome and Bardet-Biedl Syndrome are thought to be caused by deficits in the trafficking between the rod inner and outer segments due to mutated cilia (<xref rid="ref133" ref-type="bibr">Waters and Beales, 2011</xref>; <xref rid="ref125" ref-type="bibr">Tsang et al., 2018</xref>; <xref rid="ref31" ref-type="bibr">Forsythe and Beales, 2013</xref>). Genes encoding trafficking proteins such as <italic toggle="yes">MYO7A</italic> (<xref rid="ref134" ref-type="bibr">Williams and Lopes, 2011</xref>), <italic toggle="yes">PCDH15</italic> (<xref rid="ref2" ref-type="bibr">Ahmed et al., 2003</xref>), and <italic toggle="yes">USH2A</italic> can have profound adverse effects on photoreceptors when disrupted, such as, impaired intracellular directional transport, impaired outer segment formation (<xref rid="ref95" ref-type="bibr">&#214;zg&#252;l et al., 2011</xref>), mislocalized proteins (<xref rid="ref149" ref-type="bibr">Zhang et al., 2015</xref>), and misrouting of opsins (<xref rid="ref47" ref-type="bibr">Jacobson et al., 2008</xref>; <xref rid="ref112" ref-type="bibr">Reiter and Leroux, 2017</xref>). The pathways to apoptosis of ciliopathies are not fully understood but may also be due to ER stress. In many cases multiple pathways to apoptosis may be recruited or are not completely known.</p><p>Cone death is secondary to that of rods and follows rod death. The factors leading to cone degeneration have remained somewhat elusive, but there are four prevailing hypotheses. First, rods typically provide the trophic survival factor, rod-derived cone viability factor (RdCVF), to cones to promote survival (<xref rid="ref73" ref-type="bibr">L&#233;veillard et al., 2004</xref>). The reduction in RdCVF as rods degenerate could reduce the viability of cones via diminished glucose uptake. The second hypothesis is the &#8216;Cone Starvation&#8217; hypothesis. Proposed by <xref rid="ref107" ref-type="bibr">Punzo et al. (2009)</xref>, they found the mTOR pathway which is typically involved in mediating anabolic processes of cells is diminished due to low nutrient conditions, and promotes the autophagy of cones. They identified upregulation of GLUT-1 in cones, as a compensatory mechanism for the decrease in glucose. Thus, the first two hypothesis converge on a pathway involving glucose loss and cone starvation. The third hypothesis involves the increase in oxidative stressors called reactive oxygen species (ROS). Cones are especially susceptible to oxidative stress due to their high metabolic load (<xref rid="ref117" ref-type="bibr">Shen et al., 2005</xref>; <xref rid="ref44" ref-type="bibr">Hoang et al., 2002</xref>). Within the retina, rods consume 95% of the oxygen delivered by the choroid and as rods degenerate the choroid has no mechanism to autoregulate oxygen levels (<xref rid="ref144" ref-type="bibr">Yu et al., 2000</xref>). Increasing oxygen results in ROS species, which cause mitochondrial breakdown ultimately leading to apoptosis (<xref rid="ref62" ref-type="bibr">Kevany and Palczewski, 2010</xref>). Finally, microglia activation coincident with rod death may influence cone apoptosis (<xref rid="ref40" ref-type="bibr">Gupta et al., 2003</xref>; <xref rid="ref147" ref-type="bibr">Zeiss and Johnson, 2004</xref>). Microglia recruitment is a normal function of the inflammatory immune response to damage, but in many cases, it has both protective and destructive effects (<xref rid="ref9" ref-type="bibr">Block and Hong, 2005</xref>; <xref rid="ref37" ref-type="bibr">Graeber and Streit, 2010</xref>). Under these circumstances microglia release pro-inflammatory cytokines that can bind to cones and activate proapoptotic pathways (<xref rid="ref148" ref-type="bibr">Zeng et al., 2005</xref>). Evidence suggests that these pathways work in concert to produce cone degeneration.</p></sec><sec id="sec4"><label>2.2</label><title>Clinical presentation</title><p>Many identified genes causing RP affect the visual transduction cascade in rods, where mutations in many steps in phototransduction can result in photoreceptor death (<xref rid="ref101" ref-type="bibr">Phelan and Bok, 2000</xref>). As rods are the first to degenerate, patients first experience night blindness, before peripheral vision loss, and the transition from partial to complete blindness results from secondary loss of cones following rod degeneration. The clinical presentation of RP typically takes decades to evolve, and for much of the early stages, patients may not notice progressive visual changes. The diagnostic criterion for RP encompasses night blindness, peripheral field deficits, lesions within the fundus, and hypovolted electroretinogram (ERG) (<xref rid="ref82" ref-type="bibr">Michael and Fletcher, 2004</xref>; <xref rid="ref41" ref-type="bibr">Hamel, 2006</xref>; <xref rid="ref56" ref-type="bibr">Kaplan et al., 1990</xref>; <xref rid="ref7" ref-type="bibr">Baumgartner, 2000</xref>; <xref rid="ref74" ref-type="bibr">Li et al., 1995</xref>). In the early stages of RP, changes in the ERG may be the first indicator that a patient is developing RP, as the fundus can appear clear of pigmentary deposits and the patient may not report any perceptual changes to their vision.</p><p>As the disease progresses to intermediate stages, patients begin to notice worsening night vision, culminating in the inability to drive at night or navigate in dim light. In addition, patients also experience visual changes under photopic light conditions. Scotomas can appear, creating blind spots in the peripheral visual field (<xref rid="ref38" ref-type="bibr">Grover et al., 1998</xref>). Patients may also become photophobic, especially under diffuse lighting conditions, such as bright cloudy weather (<xref rid="ref93" ref-type="bibr">Otsuka et al., 2020</xref>). Color vision can be disrupted leading to dyschromatopsia specifically in blue/yellow color perception (<xref rid="ref49" ref-type="bibr">Jeffrey et al., 2014</xref>). Often patients do not seek help until their central visual acuity is compromised due to extensive cone loss, and they are no longer able to read. In this stage, the scotopic ERG is nonexistent and the photopic ERG is significantly reduced (<xref rid="ref88" ref-type="bibr">Nagy et al., 2008</xref>). Fundoscopy images show bone-spicule shaped deposits in the periphery and narrowing of retinal vasculature (<xref rid="ref74" ref-type="bibr">Li et al., 1995</xref>).</p><p>In the late stages of RP, patients are left with very little, if any, foveal vision. The fundus shows dramatic bone spicule pigmentation, thin vasculature, and optic disk discoloration. The choroid also begins to atrophy in the periphery and macular regions. With little to no vision remaining, this is the stage in which retinal prosthesis have traditionally been implemented to restore vision, given the low risk to further vision loss. Prior work shows that patients with late stage RP have a harder time using assistive technologies limiting their ability to pursue higher education and maintain jobs (<xref rid="ref20" ref-type="bibr">Chaumet-Riffaud et al., 2017</xref>). As such, vision restoration could have a large impact on patients&#8217; quality of life as they regain the ability to independently navigate. However, extensive disease mediated plasticity in the inner retina may also limit the potential quality of restored vision. These considerations demonstrate the importance for gauging the best disease stage to implement vision restoration strategies for both RP and AMD from a cost/benefit perspective.</p><p>Given the relatively simple genetic origins of most RP, gene therapies have garnered much excitement for the potential to &#8220;cure&#8221; RP by delivering the required gene to correct rod dysfunction before degeneration begins. Nevertheless, only one gene therapy has been approved by the FDA (Luxturna, Spark Therapeutics), which is approved for use in patients with Leber Congenital Amaurosis. Luxturna targets the RPE65 gene and showed improvements in the majority of patients at follow-up. While Luxturna paved the way for gene therapies it only targets 0.3&#8211;1% of RP cases (<xref rid="ref137" ref-type="bibr">Wu et al., 2023</xref>), and other gene therapies remain in the clinical trial stage. As others have reviewed the current state of gene therapies for inherited retinal diseases, we direct interested readers to <xref rid="ref3" ref-type="bibr">Amato et al. (2021)</xref>, for a more in depth discussion.</p><p>Other therapies are under development to slow the progression of RP such as injections of Rod Cone viability factor (<xref rid="ref138" ref-type="bibr">Yang et al., 2009</xref>), glucose addition (<xref rid="ref57" ref-type="bibr">Kaplan et al., 2021</xref>), or the anti-inflammatory drug dexamethasone (<xref rid="ref39" ref-type="bibr">Guadagni et al., 2019</xref>). Interestingly, these trophic drugs may also be useful for AMD as rod loss precedes cone loss and metabolic stress is a feature of both diseases. However, any benefit is only afforded after the loss of rods, and may only slow, not prevent, the loss of cones.</p></sec></sec><sec id="sec5"><label>3</label><title>Age related macular degeneration</title><sec id="sec6"><label>3.1</label><title>Etiology</title><p>The etiology and pathophysiology of AMD are more complex and less well understood than RP, but several factors significantly increase the incidence of developing AMD. While no one gene or factor will in isolation result in AMD, the largest factor contributing to disease is age. Other environmental factors include smoking (<xref rid="ref66" ref-type="bibr">Klein et al., 1993a</xref>,<xref rid="ref68" ref-type="bibr">b</xref>; <xref rid="ref119" ref-type="bibr">Smith et al., 1996</xref>), diet (<xref rid="ref19" ref-type="bibr">Chapman et al., 2019</xref>), hypertension (<xref rid="ref45" ref-type="bibr">Hogg et al., 2008</xref>; <xref rid="ref60" ref-type="bibr">Katsi et al., 2015</xref>), oxidative stress (<xref rid="ref8" ref-type="bibr">Beatty et al., 2000</xref>; <xref rid="ref115" ref-type="bibr">Shaw et al., 2016</xref>; <xref rid="ref48" ref-type="bibr">Jarrett and Boulton, 2012</xref>), alcohol intake (<xref rid="ref19" ref-type="bibr">Chapman et al., 2019</xref>), BMI, and sunlight exposure (<xref rid="ref1" ref-type="bibr">Age-Related Eye Disease Study Research Group, 2000</xref>; <xref rid="ref21" ref-type="bibr">Coleman et al., 2008</xref>), while traits not directly associated with disease progression include race (<xref rid="ref33" ref-type="bibr">Friedman et al., 1999</xref>; <xref rid="ref67" ref-type="bibr">Klein et al., 1999</xref>), iris color (<xref rid="ref24" ref-type="bibr">Cruickshanks et al., 1993</xref>; <xref rid="ref122" ref-type="bibr">Taylor et al., 1992</xref>), and gender (<xref rid="ref84" ref-type="bibr">Mousavi and Armstrong, 2013</xref>). The degree to which genes result in AMD and the severity of progression is not completely understood. However, a risk factor scale has been developed using additive odds ratios for each individual risk factor. Risk categories are low (1.0&#8211;7.90), average (8.0&#8211;28.9), moderate (29.0&#8211;100), high (101&#8211;184), severe (185&#8211;2,600) (<xref rid="ref146" ref-type="bibr">Zanke et al., 2010</xref>). With increasing risk score, patients increase the prevalence of progressing to the late-stage AMD outcomes, geographic atrophy and choroidal neovascularization. Primary genes include <italic toggle="yes">CFH</italic>, <italic toggle="yes">ARMS2</italic>, <italic toggle="yes">C3</italic>, <italic toggle="yes">CFB</italic>, and <italic toggle="yes">C2</italic>, with risk scores of 7.2, 25.4, 3.6, 0.3, and 0.3, respectively, (<xref rid="ref114" ref-type="bibr">Seddon et al., 2009</xref>).</p><sec id="sec7"><label>3.1.1</label><title>Dry AMD</title><p>The retina is one of the most metabolically expensive organs in the body (<xref rid="ref143" ref-type="bibr">Yu and Cringle, 2001</xref>; <xref rid="ref55" ref-type="bibr">Joyal et al., 2018</xref>). The function of over 91 million rods and 4.5 million cones are dependent upon proper nutrient access and waste product disposal through the RPE (<xref rid="ref142" ref-type="bibr">Young and Bok, 1969</xref>; <xref rid="ref72" ref-type="bibr">Lakkaraju et al., 2020</xref>). RPE cells are non-renewing and as we age, waste products begin to accumulate. Photoreceptors shed approximately 10% of their outer segment volume a day, which must be broken down by the RPE and the waste products trafficked out through Bruch&#8217;s Membrane and into the choroid (<xref rid="ref62" ref-type="bibr">Kevany and Palczewski, 2010</xref>; <xref rid="ref141" ref-type="bibr">Young, 1971</xref>). Certain byproducts of this process are more difficult to breakdown, such as lipofuscin, which is produced by incomplete digestion of outer segments by phagolysosomes (<xref rid="ref131" ref-type="bibr">Wang et al., 2009</xref>; <xref rid="ref61" ref-type="bibr">Keeling et al., 2018</xref>). As lipofuscin accumulates in the RPE it is converted into N-retinylidene-N-retinylethanolamine (A2E), RPE cells with high A2E generate high levels of reactive oxygen species (ROS), hydrogen peroxide and super oxide, which are toxic to RPE cells and promotes their degeneration (<xref rid="ref83" ref-type="bibr">Moreno-Garc&#237;a et al., 2018</xref>). Reactive oxygen species can further impair cellular respiration by causing mitochondrial breakdown, reducing both RPE and photoreceptor cell viability (<xref rid="ref70" ref-type="bibr">Kohen and Nyska, 2002</xref>; <xref rid="ref65" ref-type="bibr">King et al., 2004</xref>) (<xref rid="fig3" ref-type="fig">Figure 3</xref>).</p><fig position="float" id="fig3" orientation="portrait"><label>Figure 3</label><caption><p>Genes and pathogenesis of AMD. The primary hallmark of AMD is the formation of drusen which results due to impaired cholesterol transport. Age and oxidative stressors play a significant role in AMD progression. Chronic inflammation is tied to the immune response which is impaired in AMD. Proangiogenic pathways lead to the development of wet AMD. Created with <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.biorender.com" ext-link-type="uri">www.biorender.com</ext-link>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fncel-18-1502473-g003.jpg"/></fig><p>Drusen deposits form between the RPE and Bruch&#8217;s Membrane and can be classified as hard or soft (<xref rid="ref63" ref-type="bibr">Khan et al., 2016</xref>). While hard drusen are a normal part of ageing, soft drusen deposits can be the first indicator of AMD (<xref rid="ref106" ref-type="bibr">Pugazhendhi et al., 2021</xref>). The causes of these deposits are multifaceted, with factors including inflammation, oxidative stress, and various genetic components (<xref rid="ref21" ref-type="bibr">Coleman et al., 2008</xref>; <xref rid="ref34" ref-type="bibr">Friedman et al., 2004</xref>), and the shift to larger drusen bodies accompanying AMD is not fully understood. These accumulations are primarily composed of lipids, specifically cholesterol, and there are several high-density lipoprotein associated genes implicated in AMD drusen formation identified through genome wide association studies (GWAS) in human patients (<xref rid="ref110" ref-type="bibr">Rajanala et al., 2023</xref>). These genes are <italic toggle="yes">LIPC</italic>, <italic toggle="yes">CETP</italic>, <italic toggle="yes">ABCA1</italic>, and <italic toggle="yes">APOE</italic> which are involved in lipid and cholesterol transport and breakdown mechanisms (<xref rid="ref120" ref-type="bibr">Storti et al., 2017</xref>). Disruption of the normal function of these genes leads to impairment of the cholesterol transport of the retina resulting in drusen formation and inflammatory signaling (<xref rid="ref59" ref-type="bibr">Karlstetter et al., 2015</xref>; <xref rid="ref13" ref-type="bibr">Campbell and Doyle, 2013</xref>).</p><p>The complement factor pathway has been strongly implicated in the pathobiology of AMD (<xref rid="ref84" ref-type="bibr">Mousavi and Armstrong, 2013</xref>; <xref rid="ref116" ref-type="bibr">Shaw et al., 2012</xref>; <xref rid="ref76" ref-type="bibr">Lor&#233;s-Motta et al., 2018</xref>). Also known as the complement cascade, it acts through a series of protein interactions enhancing the clearance of damaged cells via the immune system. There are three pathways by which the complement cascade can be activated, the classical pathway (via antigen&#8211;antibody complexes), the alternative pathway (via spontaneous C3 hydrolysis), and the lectin pathway (via Mannose-binding lectin/MBL-associated serine proteases (MLB-MASP) complexes) (<xref rid="ref81" ref-type="bibr">Merle et al., 2015</xref>). Dysfunction in the inhibition of the alternative pathway leads to over activation of the immune response and RPE cell death. GWAS studies have shown a significant role for the Complement factor H (<italic toggle="yes">CFH</italic>) gene in AMD (<xref rid="ref116" ref-type="bibr">Shaw et al., 2012</xref>; <xref rid="ref76" ref-type="bibr">Lor&#233;s-Motta et al., 2018</xref>). Since CFH inhibits the complement cascade, mutations in the gene may lead to increased anaphylatoxins, C3a and C5a, and C5 convertase which generates membrane attack complexes (MAC) thereby causing cell lysis (<xref rid="ref98" ref-type="bibr">Parente et al., 2017</xref>).</p></sec><sec id="sec8"><label>3.1.2</label><title>Choroidal neovascularized AMD</title><p>While choroidal neovascularized (CNV) AMD, commonly referred to as wet AMD, is less common than non-neovascularized AMD it is responsible for 90% of blindness in patients. In wet AMD, blood and/or serum leak into the subretinal space due to changes in the vascularization of the choroid. As wet AMD is a progression of dry AMD, many of the factors promoting vascularization originate from the dry pathobiology. Increases in inflammatory factors and dysfunction of the complement pathway eventually leads to the production of pro-angiogenic factors, however the reason not all AMD cases progress to CNV is not well understood. There are three primary angiogenic factors that are thought to cause vascularization that most likely work together, recruitment of macrophages, vascular growth factors, and vascular endothelial growth factors (<xref rid="ref106" ref-type="bibr">Pugazhendhi et al., 2021</xref>).</p><p>First, macrophages are recruited due to immune response and can be pro-inflammatory (M1) and anti-inflammatory (M2) (<xref rid="ref26" ref-type="bibr">Epelman et al., 2014</xref>). Research has shown that both types of macrophages are recruited in the development of CNV, however shifts in macrophage polarization from M1 to M2 resulted in increased angiogenesis (<xref rid="ref50" ref-type="bibr">Jetten et al., 2014</xref>; <xref rid="ref145" ref-type="bibr">Zandi et al., 2015</xref>). In studies where macrophages were depleted CNV was reduced but not eliminated (<xref rid="ref27" ref-type="bibr">Espinosa-Heidmann et al., 2003</xref>). However, in mouse models that possess macrophage deficiencies CNV was shown to develop (<xref rid="ref4" ref-type="bibr">Ambati et al., 2003</xref>). Thus, the role of macrophages in AMD is still unclear.</p><p>Second, the hormone angiopoietin 2 (Ang2) is found in elevated levels of patients with nvAMD (<xref rid="ref91" ref-type="bibr">Ng et al., 2017</xref>). Ang2 is an antagonist for the transmembrane receptor Tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 2 (Tie2). High levels of Ang2 antagonize Tie2 and have been shown to result in abnormal vasculature growth and permeability (<xref rid="ref78" ref-type="bibr">Maisonpierre et al., 1997</xref>). Finally, vascular endothelial growth factors (VEGF), specifically VEGF-A normally promotes vascular proliferation (<xref rid="ref23" ref-type="bibr">Coultas et al., 2005</xref>), however it is strongly upregulated under oxidative stress (<xref rid="ref113" ref-type="bibr">Rossino et al., 2020</xref>).</p></sec></sec><sec id="sec9"><label>3.2</label><title>Clinical presentation</title><p>AMD can be clinically classified into five stages. Stage 1 manifests as small drusen deposits that are less than 63&#8201;&#956;m in diameter and is typically diagnosed at routine optometry visits. In Stage 2, drusen deposits become larger than 63&#8201;&#956;m, but smaller than 125&#8201;&#956;m. Stage 3 is classified as &#8216;intermediate AMD&#8217;, where drusen deposits become over 125&#8201;&#956;m and the retinal pigment epithelium (RPE) begins to show abnormalities. Patients with early to intermediate AMD typically perform well on high contrast, high luminance best-corrected visual acuity tasks (<xref rid="ref105" ref-type="bibr">Pondorfer et al., 2019</xref>). Interestingly, low luminance tasks show the most pronounced effects of visual impairment in early AMD (<xref rid="ref17" ref-type="bibr">Chandramohan et al., 2016</xref>; <xref rid="ref94" ref-type="bibr">Owsley et al., 2016</xref>; <xref rid="ref92" ref-type="bibr">Nigalye et al., 2022</xref>). This shows the importance of parafoveal rod vision, which can precede inner macular cone loss, resulting in scotopic visual acuity deficits (<xref rid="ref89" ref-type="bibr">Nebbioso et al., 2014</xref>). Stage 4, or advanced AMD shows RPE damage and geographic atrophy of photoreceptors. The final stage is the transition from non-neovascularized (dry) to neovascularized (wet) AMD (<xref rid="ref30" ref-type="bibr">Ferris et al., 2013</xref>). Patients with severe AMD can eventually experience bilateral macular vision loss. Complete loss of macular vision affects 15&#8211;20 degrees of the visual field (<xref rid="ref71" ref-type="bibr">Kolb, n.d.</xref>). From the age of 65 to 80 the prevalence of developing intermediate, geographic, and neovascular AMD increase from 5.4 to 23.6%, 0.3 to 6.9%, and 0.4 to 8.2%, respectively (<xref rid="ref34" ref-type="bibr">Friedman et al., 2004</xref>; <xref rid="ref140" ref-type="bibr">Yonekawa and Kim, 2015</xref>).</p><p>Significant visual impairment occurs with progression to either the geographic atrophy or neovascularized forms of AMD (<xref rid="fig1" ref-type="fig">Figure 1</xref>, right middle &amp; bottom). Vision loss following diagnosis of neovascular AMD is rapid (<xref rid="ref85" ref-type="bibr">Munk et al., 2012</xref>) leading to a rapid decline in quality of life. In one study, patients with vision limited to light perception stated they would be willing to trade 60% of their remaining lifespan to regain perfect vision (<xref rid="ref11" ref-type="bibr">Brown et al., 2000</xref>). Clearly, the AMD population stands to greatly benefit from vision restoration technologies, yet most vision restoration research has been focused on retinitis pigmentosa (see <xref rid="tab1" ref-type="table">Table 1</xref>).</p><table-wrap position="float" id="tab1" orientation="portrait"><label>Table 1</label><caption><p>Current state of optoelectronic and optogenetic vision restoration.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Name</th><th align="left" valign="top" rowspan="1" colspan="1">Group/company</th><th align="left" valign="top" rowspan="1" colspan="1">Type</th><th align="left" valign="top" rowspan="1" colspan="1">Disease</th><th align="left" valign="top" rowspan="1" colspan="1">Outcome</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Argus 1</td><td align="left" valign="top" rowspan="1" colspan="1">Second Sight Medical Products</td><td align="left" valign="top" rowspan="1" colspan="1">Optoelectronic: Epiretinal</td><td align="left" valign="top" rowspan="1" colspan="1">RP</td><td align="left" valign="top" rowspan="1" colspan="1">- Elicited phosphenes.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IMI</td><td align="left" valign="top" rowspan="1" colspan="1">IMI Intelligent Medical Implants</td><td align="left" valign="top" rowspan="1" colspan="1">Optoelectronic: Epiretinal</td><td align="left" valign="top" rowspan="1" colspan="1">RP</td><td align="left" valign="top" rowspan="1" colspan="1">- Elicited phosphenes.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Epi-ret-3</td><td align="left" valign="top" rowspan="1" colspan="1">Optoelectronic: Epiretinal</td><td align="left" valign="top" rowspan="1" colspan="1">Optoelectronic: Epiretinal</td><td align="left" valign="top" rowspan="1" colspan="1">RP</td><td align="left" valign="top" rowspan="1" colspan="1">- Only assessed for safety.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Argus II</td><td align="left" valign="top" rowspan="1" colspan="1">Second Sight Medical Products</td><td align="left" valign="top" rowspan="1" colspan="1">Optoelectronic: Epiretinal</td><td align="left" valign="top" rowspan="1" colspan="1">RP</td><td align="left" valign="top" rowspan="1" colspan="1">- FDA approval.<break/>- 9/13 patients had light perception after 10&#8201;years.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IRIS V1</td><td align="left" valign="top" rowspan="1" colspan="1">Pixium Vision SA</td><td align="left" valign="top" rowspan="1" colspan="1">Optoelectronic: Epiretinal</td><td align="left" valign="top" rowspan="1" colspan="1">RP</td><td align="left" valign="top" rowspan="1" colspan="1">- Elicited phosphenes.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IRIS V2</td><td align="left" valign="top" rowspan="1" colspan="1">Pixium Vision SA</td><td align="left" valign="top" rowspan="1" colspan="1">Optoelectronic: Epiretinal</td><td align="left" valign="top" rowspan="1" colspan="1">RP</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Alpha AMS</td><td align="left" valign="top" rowspan="1" colspan="1">Retina Implant AG</td><td align="left" valign="top" rowspan="1" colspan="1">Optoelectronic: Subretinal</td><td align="left" valign="top" rowspan="1" colspan="1">RP</td><td align="left" valign="top" rowspan="1" colspan="1">- Light perception was observed in 13/15 patients.<break/>- Grating acuity: 0.1 to 3.3&#8201;cycles per degree.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Alpha IMS</td><td align="left" valign="top" rowspan="1" colspan="1">Retina Implant AG</td><td align="left" valign="top" rowspan="1" colspan="1">Optoelectronic: Subretinal</td><td align="left" valign="top" rowspan="1" colspan="1">RP</td><td align="left" valign="top" rowspan="1" colspan="1">- Grating acuity: 0.1 to 3.3&#8201;cycles per degree.<break/>- 86% were able to perceive light.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bionic Eye</td><td align="left" valign="top" rowspan="1" colspan="1">Center for Eye Research Australia</td><td align="left" valign="top" rowspan="1" colspan="1">Optoelectronic: Suprachoroidal</td><td align="left" valign="top" rowspan="1" colspan="1">RP</td><td align="left" valign="top" rowspan="1" colspan="1">- Above chance performance on Basic Assessment of Light and Motion (BaLM) test<break/>- 2.62 logMAR visual acuity</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RTx-015</td><td align="left" valign="top" rowspan="1" colspan="1">Ray Therapeutics</td><td align="left" valign="top" rowspan="1" colspan="1">Optogenetics</td><td align="left" valign="top" rowspan="1" colspan="1">RP</td><td align="left" valign="top" rowspan="1" colspan="1">- No results posted</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RST-001</td><td align="left" valign="top" rowspan="1" colspan="1">AbbVie</td><td align="left" valign="top" rowspan="1" colspan="1">Optogenetics</td><td align="left" valign="top" rowspan="1" colspan="1">RP</td><td align="left" valign="top" rowspan="1" colspan="1">- Only assessed for safety.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RESTORE</td><td align="left" valign="top" rowspan="1" colspan="1">Nanoscope Therapeutics Inc</td><td align="left" valign="top" rowspan="1" colspan="1">Optogenetics</td><td align="left" valign="top" rowspan="1" colspan="1">RP</td><td align="left" valign="top" rowspan="1" colspan="1">- No results posted</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PIONEER</td><td align="left" valign="top" rowspan="1" colspan="1">GenSight Biologics</td><td align="left" valign="top" rowspan="1" colspan="1">Optogenetics</td><td align="left" valign="top" rowspan="1" colspan="1">RP</td><td align="left" valign="top" rowspan="1" colspan="1">- No results posted</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">vMCO-I</td><td align="left" valign="top" rowspan="1" colspan="1">Nanoscope Therapeutics Inc.</td><td align="left" valign="top" rowspan="1" colspan="1">Optogenetics</td><td align="left" valign="top" rowspan="1" colspan="1">RP</td><td align="left" valign="top" rowspan="1" colspan="1">- No results posted</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PRIMA</td><td align="left" valign="top" rowspan="1" colspan="1">Pixium Vision SA</td><td align="left" valign="top" rowspan="1" colspan="1">Optoelectronic: Subretinal</td><td align="left" valign="top" rowspan="1" colspan="1">AMD</td><td align="left" valign="top" rowspan="1" colspan="1">- Prelim results in 5 patients showed improved light perception.<break/>- No adverse effects on peripheral vision.</td></tr></tbody></table></table-wrap><p>In the absence of vision restoration therapies, a large effort has been focused on slowing the progression of AMD. Given the apparent role of inflammation and immune response in AMD, multiple classes of anti-inflammatory drugs have been tested on AMD, namely, corticosteroids, nonsteroidal anti-inflammatory drugs, immunosuppressants, and biologics (<xref rid="ref132" ref-type="bibr">Wang et al., 2011</xref>), however, there has been little success in slowing the progression of dry AMD and to date there is no standard treatment. Currently, anti-VEGF medications such as, ranibizumab and bevacizumab are the only available treatments for patients with neovascular AMD, and these have good efficacy at slowing the progression of CNV and prolonging visual acuity (<xref rid="ref103" ref-type="bibr">Pieramici and Rabena, 2008</xref>). However, in six clinical trials for anti-VEGF medication 30&#8211;98% of patients eyes still developed macular atrophy at follow-up (<xref rid="ref32" ref-type="bibr">Foss et al., 2022</xref>). Because these drugs do not fully prevent the disease from progressing to vision loss, there exists a strong need for vision restoration technologies in AMD, despite the success of disease slowing therapies.</p></sec></sec><sec id="sec10"><label>4</label><title>Vision restoration and disease differences</title><p>Optoelectronic prosthetics have been under development since the 1990&#8217;s, however, only one device, the now defunct Argus II (Second Sight, Sylmar CA), has received FDA approval under a humanitarian device exemption. These devices were implanted between 2007 and 2019 (<xref rid="ref111" ref-type="bibr">Ramirez et al., 2023</xref>). While hailed as a breakthrough, the low acuity of restored visual percepts and invasive nature of the device precluded use in the much larger AMD patient population. The fundamental technologies for optoelectronic vision restoration have since evolved to greatly decrease effective pixel size, promising higher acuity of restored vision. The Pixium Prima device (Science Corporation, Alameda CA), offers a theoretical acuity of up to 20/440 (<xref rid="ref96" ref-type="bibr">Palanker, 2021</xref>), and is currently the only optoelectronic vision restoration technology currently in clinical trials. Moreover, it is the only vision restoration technology of any kind targeting AMD in clinical trials. Despite these engineering advances, several factors limit the wide adoption of retinal prosthesis. First, electrodes still cannot be made small enough to match photoreceptor resolution. Second, optoelectronics can be bulky and require invasive surgery. Third, optoelectronics in AMD patients may create off-target stimulation, since electrical stimulation could activate spared retina surrounding geographic atrophy. Finally, from a business standpoint, retinal prosthetics are complex and invasive implantable medical devices, with a high cost for development and regulatory approval. For a detailed review on the current state of optoelectronics please see (<xref rid="ref5" ref-type="bibr">Ayton et al., 2019</xref>).</p><p>The rapid development of optogenetic technologies over the last decade has fueled innovation in genetic vision restoration strategies. This approach has garnered much excitement due to the simplicity of the design, and the visual acuity it could theoretically achieve, although it does carry the complexity and risks common to any gene therapy, which are not insignificant (<xref rid="ref75" ref-type="bibr">Lindner et al., 2022</xref>). In addition, given most non-native light sensing mechanisms cannot match the exquisite sensitivity and dynamic range of our native photoreceptors, external hardware in the form of light amplification goggles, are likely to be required to achieve vision across a range of common conditions. This adds additional cost and complexity to optogenetic strategies for vision restoration. There are currently five ongoing clinical trials assessing the feasibility and safety of optogenetics in RP patients, but none in AMD patients. In theory optogenetics could be utilized in both RP and AMD patients, however, there are several factors that may limit feasibility in AMD. Since AMD degeneration is limited primarily to the macula with vision often remaining in the periphery, controlling the spread of gene delivery will be important to prevent off target deleterious effects in spared retina (<xref rid="ref118" ref-type="bibr">Simunovic et al., 2019</xref>). In addition, viral gene delivery can result in increased inflammatory processes, which are a leading factor already present in AMD; thus, they may exacerbate the effects. Finally, light sensitive proteins need to be continuously produced for the duration of the patient&#8217;s life, but the durability of long-term protein expression with gene therapy vectors remains unknown.</p><p>RP and AMD are significantly different in the way they present and progress clinically. For example, the age of onset for RP is younger than AMD, with patients beginning to show the RP phenotype around 35&#8201;years of age (<xref rid="ref126" ref-type="bibr">Tsujikawa et al., 2008</xref>), however early onset could begin as young as 7.6&#8201;years of age (<xref rid="ref56" ref-type="bibr">Kaplan et al., 1990</xref>). The risks of developing AMD begin increasing at age 65 and the incidence of progression to severe AMD doubles by 75 (<xref rid="fig4" ref-type="fig">Figure 4</xref>). Another significant difference between RP and AMD is that rods progressively degenerate from the periphery inward in RP. In early stages, patients experience night blindness advancing to tunnel vision. In final stages, cones degrade secondary to rods leading to the loss of foveal vision resulting in bare or no light perception. In contrast, AMD patients lose rod and cone foveal and parafoveal vision first, and maintain significant peripheral rod dominated vision. The differences in the age of onset of the diseases as well as the quality of vision lost, could ultimately drive differences in the motivation of patients to obtain vision restoration. Differences in the desire to seek vision restoration therapies between RP and AMD patients, particularly when invasive or risky, should also be considered when determining potential target populations.</p><fig position="float" id="fig4" orientation="portrait"><label>Figure 4</label><caption><p>Fundoscopic images throughout disease progression with correlated functional changes for RP and AMD. Left: Progression of RP. In early RP bone spicules form in the outer retina, minimal vision changes. Intermediate RP shows progression of spicules and pigmentary deposits, patients experience night blindness and tunnel vision in the day. Progression to late-stage RP includes dramatic pigmentary deposits, thin vasculature, and optic disk discoloration. Patients are left with minimal photopic vision. Right: Progression of AMD. Early AMD fundus shows development of drusen in the macular region. Scotomas may be present, but patients often do not notice. Progression to geographic atrophy results in larger drusen and noticeable central vision loss. Neovascularized AMD is the most significant loss of central vision. Blood and serum leakage into the subretinal space results in significant photoreceptor death. Created with <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.biorender.com" ext-link-type="uri">www.biorender.com</ext-link>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fncel-18-1502473-g004.jpg"/></fig><p>In both approaches structural remodeling of inner retinal neurons following photoreceptor degeneration may cause changes in network processing. Functional changes in the network, regardless of structural changes, could significantly change the way optogenetic or optoelectronic stimuli are encoded by the network. Structural plasticity has been studied in both RP and AMD retinas prior to and throughout degeneration. However, the effects of structural remodeling have not yet been directly tied to functional changes in circuit processing. Given that detailed functional studies in humans are not feasible, animal models are required to study circuit processing changes following degeneration. RP has many mouse models that recapitulate the disease state and allow for thorough investigation of retinal circuitry, although there are few AMD models and none that fully recapitulate the disease state. As such, much of the assumptions about functional plasticity in AMD has been inferred from RP research.</p><sec id="sec11"><label>4.1</label><title>Structural plasticity</title><p>Structural plasticity occurs throughout the nervous system; especially after injury and when presynaptic inputs are lost (<xref rid="ref12" ref-type="bibr">Butz et al., 2009</xref>). In both RP and AMD structural plasticity begins before complete degeneration of photoreceptors (<xref rid="ref51" ref-type="bibr">Jones et al., 1995</xref>; <xref rid="ref29" ref-type="bibr">Fariss et al., 2000</xref>; <xref rid="ref102" ref-type="bibr">Phillips et al., 2010</xref>; <xref rid="ref54" ref-type="bibr">Jones et al., 2003</xref>). As the retinal environment becomes unhealthy, reactive gliosis occurs to prevent further retinal damage and promote repair. However, the primary structural glial cells of the retina, M&#252;ller glia, also undergo reactive gliosis resulting in hypertrophy and glial scarring (<xref rid="ref36" ref-type="bibr">Graca et al., 2018</xref>). Glial scarring can be a significant hurdle to subretinal prosthetic vision restoration as it creates an additional barrier between stimulating electrodes and target neurons (<xref rid="ref36" ref-type="bibr">Graca et al., 2018</xref>). In addition, as photoreceptors degenerate and second order neurons lose their connections, dendrite retraction occurs which is followed by neurite expansion in search of new presynaptic targets. Generally, RP and AMD both exhibit similar structural changes after degeneration of photoreceptors, despite their difference in causes (<xref rid="ref51" ref-type="bibr">Jones et al., 1995</xref>). This may indicate that loss of input and not disease origin is a major driver of structural plasticity, however this question is far from settled.</p><p><xref rid="ref51" ref-type="bibr">Jones et al. (1995)</xref> have provided an extensive categorization of the structural changes in RP between human and animal model retinas. Primary hallmarks of structural remodeling after degeneration include second order neuron dendrite retraction, bipolar cell death, second order neurite expansion, and gliosis. While the severity of remodeling depends on each RP variant, the basics of remodeling remain the same. As rods degenerate, rod bipolar cells retract their dendrites and form new contacts with remaining cones, prolonging signaling (<xref rid="ref99" ref-type="bibr">Peng et al., 2000</xref>). As cones begin to degenerate, all bipolar cells retract their dendrites and send ectopic processes into the inner plexiform layer (<xref rid="ref102" ref-type="bibr">Phillips et al., 2010</xref>). Cone death initiates M&#252;ller glia hypertrophy and the formation of a glial scar. M&#252;ller glial cell bodies also migrate into the inner nuclear layer. Both GABAergic and glycinergic amacrine cells have also been found to ectopically migrate out of the inner nuclear layer. Finally, once cells within the inner nuclear layer lose all inputs from photoreceptors, they begin sending neurite projections both into the inner plexiform layer and outer nuclear layer (<xref rid="ref52" ref-type="bibr">Jones et al., 2016</xref>). These projections seem to have no specificity in their targets and the functional impact of these aberrant connections on signal encoding has not yet been explored.</p><p>In addition, the primary glutamate receptor on rod bipolar and ON-cone bipolar cells (mGluR6) also significantly decreases with degeneration in a mouse model of RP (<xref rid="ref108" ref-type="bibr">Puthussery et al., 2009</xref>). Receptor changes could be deleterious to vision restoration strategies. However, most vision restoration strategies target cells in the inner nuclear or ganglion cell layer and loss of mGlur6 on ON-cone dendrites will have little effect on encoding of prosthetic stimuli.</p><p>Comparative studies have shown that RP and AMD human retinas exhibit similar gross structural remodeling after degeneration. AMD retinas exhibit gliosis of M&#252;ller cells, translocation of glycinergic amacrine cells, and ectopic processes of GABAergic amacrine cells (<xref rid="ref53" ref-type="bibr">Jones et al., 2016</xref>; <xref rid="ref121" ref-type="bibr">Sullivan et al., 2003</xref>). This remodeling is especially severe directly over drusen deposits, but there is extensive remodeling in areas where no drusen deposits are found, suggesting the degree of remodeling is not restricted to the bounds of macular drusen formation. The progression of remodeling is also noticeably faster than in RP and occurs even when rod photoreceptors are still present (<xref rid="ref53" ref-type="bibr">Jones et al., 2016</xref>). This may indicate separate mechanisms by which structural plasticity is initiated in RP and AMD retinas and indicates that factors beyond loss of inputs contribute to changes. We return to this point of quicker remodeling and its possible impact on functional responses in the sections below.</p></sec><sec id="sec12"><label>4.2</label><title>Functional plasticity</title><p>Changes in circuit structure will certainly cause changes in function, but it is also possible to have functional changes in a network beyond what can be seen structurally. Here we define structural plasticity as discrete changes to cell location, dendrite morphology, or receptor number and functional plasticity as changes in the electrical, or biochemical activity within and between cells. There is still a large gap in our understanding of how the retina functionally changes after degeneration (<xref rid="ref109" ref-type="bibr">Puthussery and Taylor, 2010</xref>). For example, although animal models of RP have been used extensively to characterize physiological responses to prosthetic electrical stimulation or optogenetic stimulation, we still do not fully understand the complexities of how these responses are generated by spared retinal circuitry. In particular, inhibition is a key circuit element shaping retinal response during natural vision, however, few studies have examined if or how inhibitory function is altered following degeneration (<xref rid="ref46" ref-type="bibr">Ivanova et al., 2016</xref>; <xref rid="ref79" ref-type="bibr">Margolis and Detwiler, 2011</xref>; <xref rid="ref139" ref-type="bibr">Ye and Goo, 2007</xref>; <xref rid="ref43" ref-type="bibr">Haq et al., 2014</xref>), although recent work suggests that it is disrupted (<xref rid="ref15" ref-type="bibr">Carleton and Oesch, 2022</xref>; <xref rid="ref16" ref-type="bibr">Carleton and Oesch, 2024</xref>). In this section, we cover the known functional changes of the retina in response to prosthetic stimuli in mouse models of RP and AMD.</p><p>Animal models are a powerful tool used to assess circuit function. There are over 10 different mouse models of retinitis pigmentosa; the <italic toggle="yes">rd1</italic> and <italic toggle="yes">rd10</italic> mouse lines being the two most commonly used. Both the <italic toggle="yes">rd1</italic> and <italic toggle="yes">rd10</italic> models of retinitis pigmentosa are valuable models of autosomal recessive retinitis pigmentosa in humans (<xref rid="ref18" ref-type="bibr">Chang et al., 2002</xref>). Both of these models have mutations in the gene <italic toggle="yes">PDEb6</italic>, which disrupt the function of the beta subunit of phosphodiesterase resulting in excitotoxic cGMP (see <xref rid="fig2" ref-type="fig">Figure 2</xref>), similar to common human forms of RP.</p><p>Although there are many animal models trying to recapitulate the AMD disease state, due to the diffuse and incompletely understood causes, no one model fully captures all the factors leading to atrophy of photoreceptors (<xref rid="ref100" ref-type="bibr">Pennesi et al., 2012</xref>). The models that can recapitulate both an &#8216;AMD like state&#8217; and geographic atrophy are not consistent across all animals, requiring large cohorts and continued genetic modification. Due to these challenges, there has been limited work on the functional changes in the retina in AMD. One recent model that has been used to examine retinal function is laser induced geographic atrophy. While this model does mimic some features of AMD, such as central photoreceptor death and recruitment of the complement pathway, it does not include the chronic inflammatory or pro-angiogenic phenotypes (<xref rid="ref64" ref-type="bibr">Khan et al., 2023</xref>), which may drive both functional and structural plasticity beyond what is caused by the loss of photoreceptors. This gap in knowledge about retinal function in the AMD disease state presents a significant challenge for the development and implementation of vision restoration strategies in AMD.</p><sec id="sec13"><label>4.2.1</label><title>Functional changes in RP</title><p>One of the best documented functional changes following photoreceptor loss in mouse models of RP is increased spontaneous activity, which tends to be oscillatory in nature. The frequency of the oscillation differs between the two most prominent RP mouse models; 1&#8211;2&#8201;Hz in the <italic toggle="yes">rd1</italic> model and 4&#8211;8&#8201;Hz in the <italic toggle="yes">rd10</italic> model (<xref rid="ref124" ref-type="bibr">Trenholm and Awatramani, 2015</xref>). While the locus of the spontaneous oscillation remains consistent between the two strains, the cause of the different frequencies remains unknown. Prior research has clearly indicated that the gap junction between the AII amacrine cell and ON-Cone Bipolar cell to be necessary for this aberrant spontaneous activity (<xref rid="ref46" ref-type="bibr">Ivanova et al., 2016</xref>). While the phenomenon has been well documented, the disease mechanisms that cause this change are unknown. One hypothesis is that network hyperpolarization due to deafferentation may play a role, however, the observation that not all RP models show the same phenotype reveals our incomplete understanding (<xref rid="ref124" ref-type="bibr">Trenholm and Awatramani, 2015</xref>).</p><p>Much of the research devoted to understanding aberrant spontaneous activity after degeneration has focused on the deleterious effect on signal to noise for processing restored signals. Spontaneous oscillations will significantly degrade the encoding of prosthetic signals in the retina and in higher visual areas in the brain (<xref rid="ref46" ref-type="bibr">Ivanova et al., 2016</xref>). Not only do oscillations increase background non-visual noise, but they can also exhibit spatial correlations, potentially disrupting spatial signaling as well (<xref rid="ref15" ref-type="bibr">Carleton and Oesch, 2022</xref>). This may indicate functional deficits of inhibition that normally limits the spread of information across the retina (<xref rid="ref15" ref-type="bibr">Carleton and Oesch, 2022</xref>). These functional changes may make restored signals less discriminable, and also confound normal spatiotemporal integration. These challenges would likely exist for both prosthetic and optogenetic restoration strategies.</p><p>Additionally, functional changes can be found in the retina&#8217;s ability to decompose the visual signal into parallel information channels, such as the ON and OFF pathways that encode the increment and decrement of light, respectively. It was previously shown in normal animals that ON and OFF RGC&#8217;s have distinct excitation to inhibition (E/I) ratios in response to light stimuli (<xref rid="ref87" ref-type="bibr">Murphy and Rieke, 2008</xref>; <xref rid="ref97" ref-type="bibr">Pang et al., 2003</xref>). We recently investigated the E/I ratios in both <italic toggle="yes">rd10</italic> and <italic toggle="yes">wt</italic> animals in response to electrical stimulation. We found that E/I ratios were broadly similar between <italic toggle="yes">rd10</italic> and wt, however there was significantly more presynaptic inhibition in the OFF pathway of <italic toggle="yes">rd10</italic> retinas compared to wt. How this will impact restored visual signals remains unknown, however, a significant challenge to any vision restoration strategy is the restoration of both ON and OFF signaling pathways, which must work together for normal vision. While it is easy to artificially generate excitation in the presence of light to recapitulate the ON pathway, creating an artificial mechanism to generate excitation in the OFF pathway in response to decrements of light remains a persistent challenge for both prosthetics and optogenetics. Taken together these considerations demonstrate the importance of examining functional changes after degeneration of photoreceptors across disease models.</p></sec><sec id="sec14"><label>4.2.2</label><title>Functional changes in the geographic atrophy model for AMD</title><p>In the laser induced GA mouse model, lesions to the pigment epithelium resulted in GA with similarities to AMD patients. Photoreceptor degeneration presents quickly in this model akin to that observed in patients with CNV. To date, ERG analysis has been used to confirm a reduction in the A-wave (photoreceptors) and increased B-wave (inner retina), but more detailed studies assessing retinal function MEA analysis or single cell electrophysiology following GA have not been done.</p><p>Alternatively, there have been studies assessing the impacts of local and acute photoreceptor degeneration on inner retinal circuitry, while not trying to recapitulate the &#8216;full AMD state&#8217;. To induce local degeneration, <xref rid="ref25" ref-type="bibr">Denlinger et al. (2020)</xref> placed an electrode array in healthy retina, separating the photoreceptor layer from the pigment epithelium. This resulted in photoreceptor death over the implant presumably due to nutrient loss. Retinal responses recorded on an MEA displayed increased spontaneous activity in RGC&#8217;s mediated by increased retinoic acid (<xref rid="ref25" ref-type="bibr">Denlinger et al., 2020</xref>). This hyperexcitability was limited to ganglion cells and did not seem to be originating from the same circuit found in RP mouse models (<xref rid="ref124" ref-type="bibr">Trenholm and Awatramani, 2015</xref>; <xref rid="ref123" ref-type="bibr">Telias et al., 2019</xref>). These findings suggest that acute induction of local degeneration may not be equivalent to progressive global degeneration.</p><p>At a finer scale, in an acute rod photoreceptor ablation paradigm, the healthy retina was able to functionally compensate for the loss of 50% of rods, inner retinal inhibitory signals were dampened as a compensatory mechanism to maintain rod bipolar voltage output and cone signaling remained unaffected (<xref rid="ref14" ref-type="bibr">Care et al., 2020</xref>). These results indicate that the retina is capable of fast compensation and plasticity when photoreceptors are lost, however the extent to which acute ablation studies are representative of the full AMD disease state is unclear. As discussed above, structural plasticity begins occurring in disease before all rods are lost in both AMD and RP, and as such acute ablation would not include these changes. Nonetheless, these results aid in our understanding of reactive changes within the retina after photoreceptor loss.</p></sec></sec></sec><sec sec-type="discussion" id="sec15"><label>5</label><title>Discussion</title><p>In this review, we compared RP and AMD through the lens of vision restoration. Despite the much greater prevalence of AMD, RP has received far more attention both in preclinical and clinical work regarding vision restoration therapies. While the hope may be that successful vision restoration technologies for RP can eventually be translated to AMD patients following validation of safety and efficacy, there is little functional neural work in AMD to determine if similar outcomes could be expected between RP and AMD. It may be possible that the quick nature of photoreceptor degeneration in AMD will limit the functional changes in the retina, reducing the need to accommodate for circuit dysfunction, such as decreased signal to noise and increased inhibition of the OFF pathway, however, the existence of structural changes prior to photoreceptor degeneration in AMD indicates a more complex scenario. Clearly, more work is needed to explore these ideas.</p><p>While patient welfare is the primary goal in the development of vision restoration technologies, commercialization and economic impact are nonetheless important to their success as a business model, which ultimately leads to patient access. The larger population of patients with AMD may result in a more sustainable business model, as many prior prosthetics ventures for RP patients have failed due to the high cost of development and a small patient pool. Furthermore, the Argus II provides the only evidence for an approved implant and was only approved for use in patients with bare or no light perception limiting the number of patients within criteria. While cost-effectiveness increased with implantation, and societal willingness to pay for the Argus II was below the threshold of maximal payment (<xref rid="ref127" ref-type="bibr">Vaidya et al., 2014</xref>), the economic impact of the Argus II was still low. In the US alone, the economic value of the Argus II, if all RP patients with little to no light perception were implanted, would have been $200 million. However, the true economic value was only $12.8 million, with $100 million of federal funding invested (<xref rid="ref130" ref-type="bibr">Walsh et al., 2018</xref>). Given the huge cost for bringing either an optogenetic, or optoelectronic device to market, the benefit for implementation of a common strategy across both AMD and RP is clear.</p><p>These considerations motivate a need for the development of more animal models in AMD and more comparative preclinical work between RP and AMD. Development and validation of new animal models can be time consuming. Therefore, before new AMD models come online, we may be able to leverage the extensive catalogue of RP models to shed new light onto vision restoration in AMD. For example, given the difference in time course between RP and AMD in humans, we could use existing RP models (<xref rid="ref18" ref-type="bibr">Chang et al., 2002</xref>) with different degeneration time courses to examine how disease time-course affects function. We may be able to translate these findings to vision restoration strategies in AMD. By cataloging how blind retinas respond to a signal restoration in a broad variety of models of degeneration we can strategically design and implement stimulation parameters based on grouped disease phenotypes rather than a &#8216;one-size-fits-all&#8217; manner. This should deliver the best quality vision restoration to a broader population in need.</p></sec></body><back><sec sec-type="author-contributions" id="sec17"><title>Author contributions</title><p>MC: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing &#8211; original draft, Writing &#8211; review &amp; editing. NO: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing &#8211; original draft, Writing &#8211; review &amp; editing.</p></sec><sec sec-type="COI-statement" id="sec19"><title>Conflict of interest</title><p>NWO has an equity interest in Nanovision Biosciences, Inc. and serves on the Scientific Advisory Board. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict-of-interest policies. NWO is listed on US Patent App. 17/080,779: Retinal Prostheses (2021).</p><p>The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec id="sec16"><title>Generative AI statement</title><p>The authors declare that no Gen AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="sec20"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab id="coll1">Age-Related Eye Disease Study Research Group</collab></person-group> (<year>2000</year>). <article-title>Risk factors associated with age-related macular degeneration</article-title>. <source>Ophthalmology</source><volume>107</volume>, <fpage>2224</fpage>&#8211;<lpage>2232</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0161-6420(00)00409-7</pub-id><pub-id pub-id-type="pmid">11097601</pub-id><pub-id pub-id-type="pmcid">PMC1470467</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmed</surname><given-names>Z. M.</given-names></name><name name-style="western"><surname>Riazuddin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bernstein</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sabar</surname><given-names>M. F.</given-names></name><etal/></person-group>. (<year>2003</year>). <article-title>PCDH15 is expressed in the neurosensory epithelium of the eye and ear and mutant alleles are responsible for both USH1F and DFNB23</article-title>. <source>Hum. Mol. Genet.</source><volume>12</volume>, <fpage>3215</fpage>&#8211;<lpage>3223</lpage>. doi: <pub-id pub-id-type="doi">10.1093/hmg/ddg358</pub-id>, PMID: <pub-id pub-id-type="pmid">14570705</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amato</surname><given-names>A.</given-names></name><name name-style="western"><surname>Arrigo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aragona</surname><given-names>E.</given-names></name><name name-style="western"><surname>Manitto</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Saladino</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bandello</surname><given-names>F.</given-names></name></person-group> (<year>2021</year>). <article-title>Gene therapy in inherited retinal diseases: an update on current state of the art</article-title>. <source>Front. Med.</source><volume>8</volume>:<fpage>750586</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmed.2021.750586</pub-id><pub-id pub-id-type="pmcid">PMC8553993</pub-id><pub-id pub-id-type="pmid">34722588</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ambati</surname><given-names>J.</given-names></name><name name-style="western"><surname>Anand</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sakurai</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lynn</surname><given-names>B. C.</given-names></name><name name-style="western"><surname>Kuziel</surname><given-names>W. A.</given-names></name><etal/></person-group>. (<year>2003</year>). <article-title>An animal model of age-related macular degeneration in senescent Ccl-2-or Ccr-2-deficient mice</article-title>. <source>Nat. Med.</source><volume>9</volume>, <fpage>1390</fpage>&#8211;<lpage>1397</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nm950</pub-id>, PMID: <pub-id pub-id-type="pmid">14566334</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ayton</surname><given-names>L. N.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dagnelie</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fujikado</surname><given-names>T.</given-names></name><name name-style="western"><surname>Goetz</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hornig</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>An update on retinal prostheses</article-title>. <source>Clin. Neurophysiol. Off. J. Int. Fed. Clin. Neurophysiol.</source><volume>131</volume>:<fpage>1383</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.clinph.2019.11.029</pub-id><pub-id pub-id-type="pmcid">PMC7198351</pub-id><pub-id pub-id-type="pmid">31866339</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Barabas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cutler Peck</surname><given-names>C.</given-names></name><name name-style="western"><surname>Krizaj</surname><given-names>D.</given-names></name></person-group> (<year>2010</year>). &#8220;<article-title>Do Calcium Channel blockers rescue dying photoreceptors in the Pde6brd1Mouse?</article-title>&#8221; in <source>Retinal degenerative diseases: Laboratory and therapeutic investigations</source>. eds. <person-group person-group-type="editor"><name name-style="western"><surname>Anderson</surname><given-names>R. E.</given-names></name><name name-style="western"><surname>Hollyfield</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>LaVail</surname><given-names>M. M.</given-names></name></person-group> (<publisher-loc>New York, NY</publisher-loc>: <publisher-name>Springer</publisher-name>), <fpage>491</fpage>&#8211;<lpage>499</lpage>.</mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baumgartner</surname><given-names>W. A.</given-names></name></person-group> (<year>2000</year>). <article-title>Etiology, pathogenesis, and experimental treatment of retinitis pigmentosa</article-title>. <source>Med. Hypotheses</source><volume>54</volume>, <fpage>814</fpage>&#8211;<lpage>824</lpage>. doi: <pub-id pub-id-type="doi">10.1054/mehy.1999.0957</pub-id><pub-id pub-id-type="pmid">10859693</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beatty</surname><given-names>S.</given-names></name><name name-style="western"><surname>Koh</surname><given-names>H.-H.</given-names></name><name name-style="western"><surname>Phil</surname><given-names>M.</given-names></name><name name-style="western"><surname>Henson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Boulton</surname><given-names>M.</given-names></name></person-group> (<year>2000</year>). <article-title>The role of oxidative stress in the pathogenesis of age-related macular degeneration</article-title>. <source>Surv. Ophthalmol.</source><volume>45</volume>, <fpage>115</fpage>&#8211;<lpage>134</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0039-6257(00)00140-5</pub-id><pub-id pub-id-type="pmid">11033038</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Block</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>J.-S.</given-names></name></person-group> (<year>2005</year>). <article-title>Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism</article-title>. <source>Prog. Neurobiol.</source><volume>76</volume>, <fpage>77</fpage>&#8211;<lpage>98</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pneurobio.2005.06.004</pub-id>, PMID: <pub-id pub-id-type="pmid">16081203</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bourne</surname><given-names>R. R. A.</given-names></name><name name-style="western"><surname>Flaxman</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Braithwaite</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cicinelli</surname><given-names>M. V.</given-names></name><name name-style="western"><surname>das</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jonas</surname><given-names>J. B.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis</article-title>. <source>Lancet Glob. Health</source><volume>5</volume>, <fpage>e888</fpage>&#8211;<lpage>e897</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S2214-109X(17)30293-0</pub-id>, PMID: <pub-id pub-id-type="pmid">28779882</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>G. C.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Kistler</surname><given-names>J.</given-names></name></person-group> (<year>2000</year>). <article-title>Utility values and age-related macular degeneration</article-title>. <source>Arch. Ophthalmol.</source><volume>118</volume>, <fpage>47</fpage>&#8211;<lpage>51</lpage>. doi: <pub-id pub-id-type="doi">10.1001/archopht.118.1.47</pub-id><pub-id pub-id-type="pmid">10636413</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butz</surname><given-names>M.</given-names></name><name name-style="western"><surname>W&#246;rg&#246;tter</surname><given-names>F.</given-names></name><name name-style="western"><surname>van Ooyen</surname><given-names>A.</given-names></name></person-group> (<year>2009</year>). <article-title>Activity-dependent structural plasticity</article-title>. <source>Brain Res. Rev.</source><volume>60</volume>, <fpage>287</fpage>&#8211;<lpage>305</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.brainresrev.2008.12.023</pub-id>, PMID: <pub-id pub-id-type="pmid">19162072</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campbell</surname><given-names>M.</given-names></name><name name-style="western"><surname>Doyle</surname><given-names>S. L.</given-names></name></person-group> (<year>2013</year>). <article-title>An eye on the future of inflammasomes and drug development in AMD</article-title>. <source>J. Mol. Med.</source><volume>91</volume>, <fpage>1059</fpage>&#8211;<lpage>1070</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00109-013-1050-0</pub-id>, PMID: <pub-id pub-id-type="pmid">23661041</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Care</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Anastassov</surname><given-names>I. A.</given-names></name><name name-style="western"><surname>Kastner</surname><given-names>D. B.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>Y. M.</given-names></name><name name-style="western"><surname>Della Santina</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>F. A.</given-names></name></person-group> (<year>2020</year>). <article-title>Mature retina compensates functionally for partial loss of rod photoreceptors</article-title>. <source>Cell Rep.</source><volume>31</volume>:<fpage>107730</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2020.107730</pub-id>, PMID: <pub-id pub-id-type="pmid">32521255</pub-id><pub-id pub-id-type="pmcid">PMC8049532</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carleton</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oesch</surname><given-names>N. W.</given-names></name></person-group> (<year>2022</year>). <article-title>Differences in the spatial fidelity of evoked and spontaneous signals in the degenerating retina</article-title>. <source>Front. Cell. Neurosci.</source><volume>16</volume>:<fpage>1040090</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fncel.2022.1040090</pub-id>, PMID: <pub-id pub-id-type="pmid">36419935</pub-id><pub-id pub-id-type="pmcid">PMC9676928</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carleton</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oesch</surname><given-names>N. W.</given-names></name></person-group> (<year>2024</year>). <article-title>Asymmetric activation of ON and OFF pathways in the degenerated retina</article-title>. <source>eNeuro</source><volume>11</volume>, <fpage>ENEURO.0110</fpage>&#8211;<lpage>ENEU24.2024</lpage>. doi: <pub-id pub-id-type="doi">10.1523/ENEURO.0110-24.2024</pub-id>, PMID: <pub-id pub-id-type="pmid">38719453</pub-id><pub-id pub-id-type="pmcid">PMC11097263</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chandramohan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stinnett</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Petrowski</surname><given-names>J. T.</given-names></name><name name-style="western"><surname>Schuman</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Toth</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Cousins</surname><given-names>S. W.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Visual function measures in early and intermediate age-related macular degeneration</article-title>. <source>Retina Phila</source><volume>36</volume>, <fpage>1021</fpage>&#8211;<lpage>1031</lpage>. doi: <pub-id pub-id-type="doi">10.1097/IAE.0000000000001002</pub-id>, PMID: <pub-id pub-id-type="pmid">26925551</pub-id><pub-id pub-id-type="pmcid">PMC4844847</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hawes</surname><given-names>N. L.</given-names></name><name name-style="western"><surname>Hurd</surname><given-names>R. E.</given-names></name><name name-style="western"><surname>Davisson</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>Nusinowitz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Heckenlively</surname><given-names>J. R.</given-names></name></person-group> (<year>2002</year>). <article-title>Retinal degeneration mutants in the mouse</article-title>. <source>Vis. Res.</source><volume>42</volume>, <fpage>517</fpage>&#8211;<lpage>525</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0042-6989(01)00146-8</pub-id><pub-id pub-id-type="pmid">11853768</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chapman</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Braakhuis</surname><given-names>A. J.</given-names></name></person-group> (<year>2019</year>). <article-title>Role of diet and food intake in age-related macular degeneration: a systematic review</article-title>. <source>Clin. Experiment. Ophthalmol.</source><volume>47</volume>, <fpage>106</fpage>&#8211;<lpage>127</lpage>. doi: <pub-id pub-id-type="doi">10.1111/ceo.13343</pub-id>, PMID: <pub-id pub-id-type="pmid">29927057</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaumet-Riffaud</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Chaumet-Riffaud</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cariou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Devisme</surname><given-names>C.</given-names></name><name name-style="western"><surname>Audo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sahel</surname><given-names>J. A.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Impact of retinitis Pigmentosa on quality of life, mental health, and employment among Young adults</article-title>. <source>Am. J. Ophthalmol.</source><volume>177</volume>, <fpage>169</fpage>&#8211;<lpage>174</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ajo.2017.02.016</pub-id>, PMID: <pub-id pub-id-type="pmid">28237413</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coleman</surname><given-names>H. R.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>C.-C.</given-names></name><name name-style="western"><surname>Ferris</surname><given-names>F. L.</given-names></name><name name-style="western"><surname>Chew</surname><given-names>E. Y.</given-names></name></person-group> (<year>2008</year>). <article-title>Age-related macular degeneration</article-title>. <source>Lancet</source><volume>372</volume>, <fpage>1835</fpage>&#8211;<lpage>1845</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(08)61759-6</pub-id>, PMID: <pub-id pub-id-type="pmid">19027484</pub-id><pub-id pub-id-type="pmcid">PMC2603424</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Comitato</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schiroli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Montanari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marigo</surname><given-names>V.</given-names></name></person-group> (<year>2020</year>). <article-title>Calpain activation is the major cause of cell death in photoreceptors expressing a rhodopsin Misfolding mutation</article-title>. <source>Mol. Neurobiol.</source><volume>57</volume>, <fpage>589</fpage>&#8211;<lpage>599</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12035-019-01723-5</pub-id>, PMID: <pub-id pub-id-type="pmid">31401765</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coultas</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chawengsaksophak</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rossant</surname><given-names>J.</given-names></name></person-group> (<year>2005</year>). <article-title>Endothelial cells and VEGF in vascular development</article-title>. <source>Nature</source><volume>438</volume>, <fpage>937</fpage>&#8211;<lpage>945</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nature04479</pub-id><pub-id pub-id-type="pmid">16355211</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cruickshanks</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>R.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>B. E. K.</given-names></name></person-group> (<year>1993</year>). <article-title>Sunlight and age-related macular degeneration: the beaver dam eye study</article-title>. <source>Arch. Ophthalmol.</source><volume>111</volume>, <fpage>514</fpage>&#8211;<lpage>518</lpage>. doi: <pub-id pub-id-type="doi">10.1001/archopht.1993.01090040106042</pub-id><pub-id pub-id-type="pmid">8470986</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Denlinger</surname><given-names>B.</given-names></name><name name-style="western"><surname>Helft</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Telias</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lorach</surname><given-names>H.</given-names></name><name name-style="western"><surname>Palanker</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>R. H.</given-names></name></person-group> (<year>2020</year>). <article-title>Local photoreceptor degeneration causes local pathophysiological remodeling of retinal neurons</article-title>. <source>JCI Insight</source><volume>5</volume>:<fpage>114</fpage>. doi: <pub-id pub-id-type="doi">10.1172/jci.insight.132114</pub-id>, PMID: <pub-id pub-id-type="pmid">31846440</pub-id><pub-id pub-id-type="pmcid">PMC7098721</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Epelman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lavine</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Randolph</surname><given-names>G. J.</given-names></name></person-group> (<year>2014</year>). <article-title>Origin and functions of tissue macrophages</article-title>. <source>Immunity</source><volume>41</volume>, <fpage>21</fpage>&#8211;<lpage>35</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2014.06.013</pub-id>, PMID: <pub-id pub-id-type="pmid">25035951</pub-id><pub-id pub-id-type="pmcid">PMC4470379</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Espinosa-Heidmann</surname><given-names>D. G.</given-names></name><name name-style="western"><surname>Suner</surname><given-names>I. J.</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>E. P.</given-names></name><name name-style="western"><surname>Monroy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Csaky</surname><given-names>K. G.</given-names></name><name name-style="western"><surname>Cousins</surname><given-names>S. W.</given-names></name></person-group> (<year>2003</year>). <article-title>Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization</article-title>. <source>Invest. Ophthalmol. Vis. Sci.</source><volume>44</volume>, <fpage>3586</fpage>&#8211;<lpage>3592</lpage>. doi: <pub-id pub-id-type="doi">10.1167/iovs.03-0038</pub-id>, PMID: <pub-id pub-id-type="pmid">12882811</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Fahim</surname><given-names>A. T.</given-names></name><name name-style="western"><surname>Daiger</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>Weleber</surname><given-names>R. G.</given-names></name></person-group> (<year>1993</year>). &#8220;<article-title>Nonsyndromic retinitis Pigmentosa overview</article-title>&#8221; in <source>GeneReviews&#174;</source>. ed. <person-group person-group-type="editor"><name name-style="western"><surname>Adam</surname><given-names>M. P.</given-names></name></person-group> (<publisher-loc>Seattle, WA</publisher-loc>: <publisher-name>University of Washington</publisher-name>).</mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fariss</surname><given-names>R. N.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z. Y.</given-names></name><name name-style="western"><surname>Milam</surname><given-names>A. H.</given-names></name></person-group> (<year>2000</year>). <article-title>Abnormalities in rod photoreceptors, amacrine cells, and horizontal cells in human retinas with retinitis pigmentosa</article-title>. <source>Am. J. Ophthalmol.</source><volume>129</volume>, <fpage>215</fpage>&#8211;<lpage>223</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0002-9394(99)00401-8</pub-id>, PMID: <pub-id pub-id-type="pmid">10682975</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferris</surname><given-names>F. L.</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>C. P.</given-names></name><name name-style="western"><surname>Bird</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chakravarthy</surname><given-names>U.</given-names></name><name name-style="western"><surname>Chew</surname><given-names>E.</given-names></name><name name-style="western"><surname>Csaky</surname><given-names>K.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Clinical classification of age-related macular degeneration</article-title>. <source>Ophthalmology</source><volume>120</volume>, <fpage>844</fpage>&#8211;<lpage>851</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ophtha.2012.10.036</pub-id><pub-id pub-id-type="pmid">23332590</pub-id><pub-id pub-id-type="pmcid">PMC11551519</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forsythe</surname><given-names>E.</given-names></name><name name-style="western"><surname>Beales</surname><given-names>P. L.</given-names></name></person-group> (<year>2013</year>). <article-title>Bardet&#8211;Biedl syndrome</article-title>. <source>Eur. J. Hum. Genet.</source><volume>21</volume>, <fpage>8</fpage>&#8211;<lpage>13</lpage>. doi: <pub-id pub-id-type="doi">10.1038/ejhg.2012.115</pub-id>, PMID: <pub-id pub-id-type="pmid">22713813</pub-id><pub-id pub-id-type="pmcid">PMC3522196</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foss</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rotsos</surname><given-names>T.</given-names></name><name name-style="western"><surname>Empeslidis</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>V.</given-names></name></person-group> (<year>2022</year>). <article-title>Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF Treatment</article-title>. <source>Ophthalmologica</source><volume>245</volume>, <fpage>204</fpage>&#8211;<lpage>217</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000520171</pub-id><pub-id pub-id-type="pmid">34695835</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedman</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Katz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bressler</surname><given-names>N. M.</given-names></name><name name-style="western"><surname>Rahmani</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tielsch</surname><given-names>J. M.</given-names></name></person-group> (<year>1999</year>). <article-title>Racial differences in the prevalence of age-related macular degeneration: the Baltimore eye survey</article-title>. <source>Ophthalmology</source><volume>106</volume>, <fpage>1049</fpage>&#8211;<lpage>1055</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0161-6420(99)90267-1</pub-id><pub-id pub-id-type="pmid">10366070</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedman</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>O'Colmain</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>Mu&#241;oz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tomany</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>McCarty</surname><given-names>C.</given-names></name><name name-style="western"><surname>de Jong</surname><given-names>P. T.</given-names></name><etal/></person-group>. (<year>2004</year>). <article-title>Prevalence of age-related macular degeneration in the United States</article-title>. <source>Arch. Ophthalmol.</source><volume>122</volume>, <fpage>564</fpage>&#8211;<lpage>572</lpage>. doi: <pub-id pub-id-type="doi">10.1001/archopht.122.4.564</pub-id><pub-id pub-id-type="pmid">15078675</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garip</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kamal</surname><given-names>A.</given-names></name></person-group> (<year>2019</year>). <article-title>Systematic review and meta-synthesis of coping with retinitis pigmentosa: implications for improving quality of life</article-title>. <source>BMC Ophthalmol.</source><volume>19</volume>:<fpage>181</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12886-019-1169-z</pub-id>, PMID: <pub-id pub-id-type="pmid">31409325</pub-id><pub-id pub-id-type="pmcid">PMC6693213</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Graca</surname><given-names>A. B.</given-names></name><name name-style="western"><surname>Hippert</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>R. A.</given-names></name></person-group> (<year>2018</year>). &#8220;<article-title>M&#252;ller glia reactivity and development of gliosis in response to pathological conditions</article-title>&#8221; in <source>Retinal degenerative diseases</source>. ed. <person-group person-group-type="editor"><name name-style="western"><surname>Ash</surname><given-names>J.</given-names></name></person-group> (<publisher-loc>Cham</publisher-loc>: <publisher-name>Springer International Publishing</publisher-name>), <fpage>303</fpage>&#8211;<lpage>308</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-3-319-75402-4_37</pub-id><pub-id pub-id-type="pmid">29721957</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graeber</surname><given-names>M. B.</given-names></name><name name-style="western"><surname>Streit</surname><given-names>W. J.</given-names></name></person-group> (<year>2010</year>). <article-title>Microglia: biology and pathology</article-title>. <source>Acta Neuropathol.</source><volume>119</volume>, <fpage>89</fpage>&#8211;<lpage>105</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00401-009-0622-0</pub-id><pub-id pub-id-type="pmid">20012873</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grover</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fishman</surname><given-names>G. A.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>J.</given-names></name></person-group> (<year>1998</year>). <article-title>Patterns of visual field progression in patients with retinitis pigmentosa</article-title>. <source>Ophthalmology</source><volume>105</volume>, <fpage>1069</fpage>&#8211;<lpage>1075</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0161-6420(98)96009-2</pub-id><pub-id pub-id-type="pmid">9627658</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guadagni</surname><given-names>V.</given-names></name><name name-style="western"><surname>Biagioni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Novelli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Aretini</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mazzanti</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Strettoi</surname><given-names>E.</given-names></name></person-group> (<year>2019</year>). <article-title>Rescuing cones and daylight vision in retinitis pigmentosa mice</article-title>. <source>FASEB J.</source><volume>33</volume>, <fpage>10177</fpage>&#8211;<lpage>10192</lpage>. doi: <pub-id pub-id-type="doi">10.1096/fj.201900414R</pub-id>, PMID: <pub-id pub-id-type="pmid">31199887</pub-id><pub-id pub-id-type="pmcid">PMC6764477</pub-id></mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>N.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>K. E.</given-names></name><name name-style="western"><surname>Milam</surname><given-names>A. H.</given-names></name></person-group> (<year>2003</year>). <article-title>Activated microglia in human retinitis pigmentosa, late-onset retinal degeneration, and age-related macular degeneration</article-title>. <source>Exp. Eye Res.</source><volume>76</volume>, <fpage>463</fpage>&#8211;<lpage>471</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0014-4835(02)00332-9</pub-id>, PMID: <pub-id pub-id-type="pmid">12634111</pub-id></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamel</surname><given-names>C.</given-names></name></person-group> (<year>2006</year>). <article-title>Retinitis pigmentosa</article-title>. <source>Orphanet J. Rare Dis.</source><volume>1</volume>:<fpage>40</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1750-1172-1-40</pub-id>, PMID: <pub-id pub-id-type="pmid">17032466</pub-id><pub-id pub-id-type="pmcid">PMC1621055</pub-id></mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wenzel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Obin</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C. K.</given-names></name><name name-style="western"><surname>Brill</surname><given-names>E.</given-names></name><name name-style="western"><surname>Krasnoperova</surname><given-names>N. V.</given-names></name><etal/></person-group>. (<year>2002</year>). <article-title>Evidence for two apoptotic pathways in light-induced retinal degeneration</article-title>. <source>Nat. Genet.</source><volume>32</volume>, <fpage>254</fpage>&#8211;<lpage>260</lpage>. doi: <pub-id pub-id-type="doi">10.1038/ng984</pub-id>, PMID: <pub-id pub-id-type="pmid">12219089</pub-id></mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haq</surname><given-names>W.</given-names></name><name name-style="western"><surname>Arango-Gonzalez</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zrenner</surname><given-names>E.</given-names></name><name name-style="western"><surname>Euler</surname><given-names>T.</given-names></name><name name-style="western"><surname>Schubert</surname><given-names>T.</given-names></name></person-group> (<year>2014</year>). <article-title>Synaptic remodeling generates synchronous oscillations in the degenerated outer mouse retina</article-title>. <source>Front. Neural Circuits</source><volume>8</volume>:<fpage>108</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fncir.2014.00108</pub-id><pub-id pub-id-type="pmid">25249942</pub-id><pub-id pub-id-type="pmcid">PMC4155782</pub-id></mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoang</surname><given-names>Q. V.</given-names></name><name name-style="western"><surname>Linsenmeier</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>C. K.</given-names></name><name name-style="western"><surname>Curcio</surname><given-names>C. A.</given-names></name></person-group> (<year>2002</year>). <article-title>Photoreceptor inner segments in monkey and human retina: mitochondrial density, optics, and regional variation</article-title>. <source>Vis. Neurosci.</source><volume>19</volume>, <fpage>395</fpage>&#8211;<lpage>407</lpage>. doi: <pub-id pub-id-type="doi">10.1017/S0952523802194028</pub-id>, PMID: <pub-id pub-id-type="pmid">12511073</pub-id></mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hogg</surname><given-names>R. E.</given-names></name><name name-style="western"><surname>Woodside</surname><given-names>J. V.</given-names></name><name name-style="western"><surname>Gilchrist</surname><given-names>S. E. C. M.</given-names></name><name name-style="western"><surname>Graydon</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>W.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>Cardiovascular disease and hypertension are strong risk factors for choroidal neovascularization</article-title>. <source>Ophthalmology</source><volume>115</volume>, <fpage>1046</fpage>&#8211;<lpage>1052.e2</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ophtha.2007.07.031</pub-id>, PMID: <pub-id pub-id-type="pmid">17953990</pub-id></mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ivanova</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yee</surname><given-names>C. W.</given-names></name><name name-style="western"><surname>Baldoni</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sagdullaev</surname><given-names>B. T.</given-names></name></person-group> (<year>2016</year>). <article-title>Aberrant activity in retinal degeneration impairs central visual processing and relies on Cx36-containing gap junctions</article-title>. <source>Exp. Eye Res.</source><volume>150</volume>, <fpage>81</fpage>&#8211;<lpage>89</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.exer.2015.05.013</pub-id>, PMID: <pub-id pub-id-type="pmid">26005040</pub-id><pub-id pub-id-type="pmcid">PMC4655183</pub-id></mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacobson</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Cideciyan</surname><given-names>A. V.</given-names></name><name name-style="western"><surname>Aleman</surname><given-names>T. S.</given-names></name><name name-style="western"><surname>Sumaroka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Roman</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>L. M.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>Usher syndromes due to MYO7A, PCDH15, USH2A or GPR98 mutations share retinal disease mechanism</article-title>. <source>Hum. Mol. Genet.</source><volume>17</volume>, <fpage>2405</fpage>&#8211;<lpage>2415</lpage>. doi: <pub-id pub-id-type="doi">10.1093/hmg/ddn140</pub-id>, PMID: <pub-id pub-id-type="pmid">18463160</pub-id><pub-id pub-id-type="pmcid">PMC2733815</pub-id></mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jarrett</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Boulton</surname><given-names>M. E.</given-names></name></person-group> (<year>2012</year>). <article-title>Consequences of oxidative stress in age-related macular degeneration</article-title>. <source>Mol. Asp. Med.</source><volume>33</volume>, <fpage>399</fpage>&#8211;<lpage>417</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.mam.2012.03.009</pub-id>, PMID: <pub-id pub-id-type="pmid">22510306</pub-id><pub-id pub-id-type="pmcid">PMC3392472</pub-id></mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeffrey</surname><given-names>B. G.</given-names></name><name name-style="western"><surname>Knighten</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Cukras</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>B. P.</given-names></name><name name-style="western"><surname>Zein</surname><given-names>W. M.</given-names></name></person-group> (<year>2014</year>). <article-title>Quantitative measurement of color discrimination with a low vision color test in patients with retinitis Pigmentosa</article-title>. <source>Invest. Ophthalmol. Vis. Sci.</source><volume>55</volume>:<fpage>1399</fpage>.</mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jetten</surname><given-names>N.</given-names></name><name name-style="western"><surname>Verbruggen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gijbels</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Post</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>de Winther</surname><given-names>M. P. J.</given-names></name><name name-style="western"><surname>Donners</surname><given-names>M. M. P. C.</given-names></name></person-group> (<year>2014</year>). <article-title>Anti-inflammatory M2, but not pro-inflammatory M1 macrophages promote angiogenesis in vivo</article-title>. <source>Angiogenesis</source><volume>17</volume>, <fpage>109</fpage>&#8211;<lpage>118</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10456-013-9381-6</pub-id><pub-id pub-id-type="pmid">24013945</pub-id></mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>B. W.</given-names></name><name name-style="western"><surname>Marc</surname><given-names>R. E.</given-names></name><name name-style="western"><surname>Pfeiffer</surname><given-names>R. L.</given-names></name></person-group> (<year>1995</year>). &#8220;<article-title>Retinal degeneration, remodeling and plasticity</article-title>&#8221; in <source>Webvision: The organization of the retina and visual system</source>. eds. <person-group person-group-type="editor"><name name-style="western"><surname>Kolb</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>R.</given-names></name></person-group> (<publisher-loc>Salt Lake City, UT</publisher-loc>: <publisher-name>University of Utah Health Sciences Center</publisher-name>).<pub-id pub-id-type="pmid">29493934</pub-id></mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>B. W.</given-names></name><name name-style="western"><surname>Pfeiffer</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Ferrell</surname><given-names>W. D.</given-names></name><name name-style="western"><surname>Watt</surname><given-names>C. B.</given-names></name><name name-style="western"><surname>Marmor</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marc</surname><given-names>R. E.</given-names></name></person-group> (<year>2016</year>). <article-title>Retinal remodeling in human retinitis pigmentosa</article-title>. <source>Exp. Eye Res.</source><volume>150</volume>, <fpage>149</fpage>&#8211;<lpage>165</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.exer.2016.03.018</pub-id>, PMID: <pub-id pub-id-type="pmid">27020758</pub-id><pub-id pub-id-type="pmcid">PMC5031517</pub-id></mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>B. W.</given-names></name><name name-style="western"><surname>Pfeiffer</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Ferrell</surname><given-names>W. D.</given-names></name><name name-style="western"><surname>Watt</surname><given-names>C. B.</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>J.</given-names></name><name name-style="western"><surname>Marc</surname><given-names>R. E.</given-names></name></person-group> (<year>2016</year>). <article-title>Retinal remodeling and metabolic alterations in human AMD</article-title>. <source>Front. Cell. Neurosci.</source><volume>10</volume>:<fpage>103</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fncel.2016.00103</pub-id><pub-id pub-id-type="pmid">27199657</pub-id><pub-id pub-id-type="pmcid">PMC4848316</pub-id></mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>B. W.</given-names></name><name name-style="western"><surname>Watt</surname><given-names>C. B.</given-names></name><name name-style="western"><surname>Frederick</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Baehr</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C. K.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>E. M.</given-names></name><etal/></person-group>. (<year>2003</year>). <article-title>Retinal remodeling triggered by photoreceptor degenerations</article-title>. <source>J. Comp. Neurol.</source><volume>464</volume>, <fpage>1</fpage>&#8211;<lpage>16</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cne.10703</pub-id><pub-id pub-id-type="pmid">12866125</pub-id></mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joyal</surname><given-names>J.-S.</given-names></name><name name-style="western"><surname>Gantner</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>L. E. H.</given-names></name></person-group> (<year>2018</year>). <article-title>Retinal energy demands control vascular supply of the retina in development and disease: the role of neuronal lipid and glucose metabolism</article-title>. <source>Prog. Retin. Eye Res.</source><volume>64</volume>, <fpage>131</fpage>&#8211;<lpage>156</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.preteyeres.2017.11.002</pub-id>, PMID: <pub-id pub-id-type="pmid">29175509</pub-id><pub-id pub-id-type="pmcid">PMC5963988</pub-id></mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaplan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bonneau</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fr&#233;zal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Munnich</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dufier</surname><given-names>J.-L.</given-names></name></person-group> (<year>1990</year>). <article-title>Clinical and genetic heterogeneity in retinitis pigmentosa</article-title>. <source>Hum. Genet.</source><volume>85</volume>, <fpage>635</fpage>&#8211;<lpage>642</lpage>. doi: <pub-id pub-id-type="doi">10.1007/BF00193589</pub-id>, PMID: <pub-id pub-id-type="pmid">2227956</pub-id></mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaplan</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Piri</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dean</surname><given-names>D. C.</given-names></name></person-group> (<year>2021</year>). <article-title>Metabolic rescue of cone photoreceptors in retinitis pigmentosa</article-title>. <source>Taiwan J. Ophthalmol.</source><volume>11</volume>, <fpage>331</fpage>&#8211;<lpage>335</lpage>. doi: <pub-id pub-id-type="doi">10.4103/tjo.tjo_46_21</pub-id>, PMID: <pub-id pub-id-type="pmid">35070660</pub-id><pub-id pub-id-type="pmcid">PMC8757513</pub-id></mixed-citation></ref><ref id="ref58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karapanos</surname><given-names>L.</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Ayton</surname><given-names>L. N.</given-names></name><name name-style="western"><surname>Kolic</surname><given-names>M.</given-names></name><name name-style="western"><surname>McGuinness</surname><given-names>M. B.</given-names></name><name name-style="western"><surname>Baglin</surname><given-names>E. K.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Functional vision in the real-world environment with a second-generation (44-channel) Suprachoroidal retinal prosthesis</article-title>. <source>Transl. Vis. Sci. Technol.</source><volume>10</volume>:<fpage>7</fpage>. doi: <pub-id pub-id-type="doi">10.1167/tvst.10.10.7</pub-id>, PMID: <pub-id pub-id-type="pmid">34383875</pub-id><pub-id pub-id-type="pmcid">PMC8362639</pub-id></mixed-citation></ref><ref id="ref59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karlstetter</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scholz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rutar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>W. T.</given-names></name><name name-style="western"><surname>Provis</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Langmann</surname><given-names>T.</given-names></name></person-group> (<year>2015</year>). <article-title>Retinal microglia: just bystander or target for therapy?</article-title><source>Prog. Retin. Eye Res.</source><volume>45</volume>, <fpage>30</fpage>&#8211;<lpage>57</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.preteyeres.2014.11.004</pub-id><pub-id pub-id-type="pmid">25476242</pub-id></mixed-citation></ref><ref id="ref60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katsi</surname><given-names>V. K.</given-names></name><name name-style="western"><surname>Marketou</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Vrachatis</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Manolis</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Nihoyannopoulos</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tousoulis</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Essential hypertension in the pathogenesis of age-related macular degeneration: a review of the current evidence</article-title>. <source>J. Hypertens.</source><volume>33</volume>, <fpage>2382</fpage>&#8211;<lpage>2388</lpage>. doi: <pub-id pub-id-type="doi">10.1097/HJH.0000000000000766</pub-id>, PMID: <pub-id pub-id-type="pmid">26536087</pub-id></mixed-citation></ref><ref id="ref61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keeling</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lotery</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Tumbarello</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Ratnayaka</surname><given-names>J. A.</given-names></name></person-group> (<year>2018</year>). <article-title>Impaired cargo clearance in the retinal pigment epithelium (RPE) underlies irreversible blinding diseases</article-title>. <source>Cells</source><volume>7</volume>:<fpage>16</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells7020016</pub-id>, PMID: <pub-id pub-id-type="pmid">29473871</pub-id><pub-id pub-id-type="pmcid">PMC5850104</pub-id></mixed-citation></ref><ref id="ref62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kevany</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Palczewski</surname><given-names>K.</given-names></name></person-group> (<year>2010</year>). <article-title>Phagocytosis of retinal rod and cone photoreceptors</article-title>. <source>Physiology</source><volume>25</volume>, <fpage>8</fpage>&#8211;<lpage>15</lpage>. doi: <pub-id pub-id-type="doi">10.1152/physiol.00038.2009</pub-id>, PMID: <pub-id pub-id-type="pmid">20134024</pub-id><pub-id pub-id-type="pmcid">PMC2839896</pub-id></mixed-citation></ref><ref id="ref63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>K. N.</given-names></name><name name-style="western"><surname>Mahroo</surname><given-names>O. A.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Mohamed</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>McKibbin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bird</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Differentiating drusen: Drusen and drusen-like appearances associated with ageing, age-related macular degeneration, inherited eye disease and other pathological processes</article-title>. <source>Prog. Retin. Eye Res.</source><volume>53</volume>, <fpage>70</fpage>&#8211;<lpage>106</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.preteyeres.2016.04.008</pub-id>, PMID: <pub-id pub-id-type="pmid">27173377</pub-id></mixed-citation></ref><ref id="ref64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>A. H.</given-names></name><name name-style="western"><surname>Soundara Pandi</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>S&#225;nchez-Breta&#241;o</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lynn</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Ratnayaka</surname><given-names>J. A.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>A laser-induced mouse model of progressive retinal degeneration with central sparing displays features of parafoveal geographic atrophy</article-title>. <source>Sci. Rep.</source><volume>13</volume>:<fpage>4194</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-023-31392-3</pub-id>, PMID: <pub-id pub-id-type="pmid">36918701</pub-id><pub-id pub-id-type="pmcid">PMC10014848</pub-id></mixed-citation></ref><ref id="ref65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>King</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>E.</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>D. G.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Dunaief</surname><given-names>J. L.</given-names></name></person-group> (<year>2004</year>). <article-title>Mitochondria-derived reactive oxygen species mediate blue light-induced death of retinal pigment epithelial cells</article-title>. <source>Photochem. Photobiol.</source><volume>79</volume>, <fpage>470</fpage>&#8211;<lpage>475</lpage>.<pub-id pub-id-type="pmid">15191057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1562/le-03-17.1</pub-id></mixed-citation></ref><ref id="ref66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klein</surname><given-names>R.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>B. E. K.</given-names></name><name name-style="western"><surname>Franke</surname><given-names>T.</given-names></name></person-group> (<year>1993a</year>). <article-title>The relationship of cardiovascular disease and its risk factors to age-related maculopathy: the beaver dam eye study</article-title>. <source>Ophthalmology</source><volume>100</volume>, <fpage>406</fpage>&#8211;<lpage>414</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0161-6420(93)31634-9</pub-id><pub-id pub-id-type="pmid">8460013</pub-id></mixed-citation></ref><ref id="ref67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klein</surname><given-names>R.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>B. E. K.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>Mares-Perlman</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Cruickshanks</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Palta</surname><given-names>M.</given-names></name></person-group> (<year>1999</year>). <article-title>Age-related maculopathy in a multiracial United States population: the national health and nutrition examination survey III</article-title>. <source>Ophthalmology</source><volume>106</volume>, <fpage>1056</fpage>&#8211;<lpage>1065</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0161-6420(99)90255-5</pub-id>, PMID: <pub-id pub-id-type="pmid">10366071</pub-id></mixed-citation></ref><ref id="ref68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klein</surname><given-names>R.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>B. E. K.</given-names></name><name name-style="western"><surname>Linton</surname><given-names>K. L. P.</given-names></name><name name-style="western"><surname>DeMets</surname><given-names>D. L.</given-names></name></person-group> (<year>1993b</year>). <article-title>The beaver dam eye study: the relation of age-related maculopathy to smoking</article-title>. <source>Am. J. Epidemiol.</source><volume>137</volume>, <fpage>190</fpage>&#8211;<lpage>200</lpage>. doi: <pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a116659</pub-id><pub-id pub-id-type="pmid">8452123</pub-id></mixed-citation></ref><ref id="ref69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koenekoop</surname><given-names>R. K.</given-names></name></person-group> (<year>2011</year>). <article-title>Why some photoreceptors die, while others remain dormant: lessons from RPE65 and LRAT associated retinal dystrophies</article-title>. <source>Ophthalmic Genet.</source><volume>32</volume>, <fpage>126</fpage>&#8211;<lpage>128</lpage>. doi: <pub-id pub-id-type="doi">10.3109/13816810.2010.544361</pub-id>, PMID: <pub-id pub-id-type="pmid">21268677</pub-id></mixed-citation></ref><ref id="ref70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kohen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nyska</surname><given-names>A.</given-names></name></person-group> (<year>2002</year>). <article-title>Invited review: oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification</article-title>. <source>Toxicol. Pathol.</source><volume>30</volume>, <fpage>620</fpage>&#8211;<lpage>650</lpage>. doi: <pub-id pub-id-type="doi">10.1080/01926230290166724</pub-id>, PMID: <pub-id pub-id-type="pmid">12512863</pub-id></mixed-citation></ref><ref id="ref71"><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Kolb</surname><given-names>H.</given-names></name></person-group> (<year>n.d.</year>) Simple Anatomy of the Retina. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://webvision.med.utah.edu/book/part-i-foundations/simple-anatomy-of-the-retina/" ext-link-type="uri">https://webvision.med.utah.edu/book/part-i-foundations/simple-anatomy-of-the-retina/</ext-link> (Accessed March 8, 2024).</mixed-citation></ref><ref id="ref72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lakkaraju</surname><given-names>A.</given-names></name><name name-style="western"><surname>Umapathy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>L. X.</given-names></name><name name-style="western"><surname>Daniele</surname><given-names>L.</given-names></name><name name-style="western"><surname>Philp</surname><given-names>N. J.</given-names></name><name name-style="western"><surname>Boesze-Battaglia</surname><given-names>K.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>The cell biology of the retinal pigment epithelium</article-title>. <source>Prog. Retin. Eye Res.</source><volume>78</volume>:<fpage>100846</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.preteyeres.2020.100846</pub-id>, PMID: <pub-id pub-id-type="pmid">32105772</pub-id><pub-id pub-id-type="pmcid">PMC8941496</pub-id></mixed-citation></ref><ref id="ref73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#233;veillard</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mohand-Sa&#239;d</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lorentz</surname><given-names>O.</given-names></name><name name-style="western"><surname>Hicks</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fintz</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Cl&#233;rin</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2004</year>). <article-title>Identification and characterization of rod-derived cone viability factor</article-title>. <source>Nat. Genet.</source><volume>36</volume>, <fpage>755</fpage>&#8211;<lpage>759</lpage>. doi: <pub-id pub-id-type="doi">10.1038/ng1386</pub-id>, PMID: <pub-id pub-id-type="pmid">15220920</pub-id></mixed-citation></ref><ref id="ref74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z.-Y.</given-names></name><name name-style="western"><surname>Possin</surname><given-names>D. E.</given-names></name><name name-style="western"><surname>Milam</surname><given-names>A. H.</given-names></name></person-group> (<year>1995</year>). <article-title>Histopathology of bone spicule pigmentation in retinitis Pigmentosa</article-title>. <source>Ophthalmology</source><volume>102</volume>, <fpage>805</fpage>&#8211;<lpage>816</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0161-6420(95)30953-0</pub-id><pub-id pub-id-type="pmid">7777280</pub-id></mixed-citation></ref><ref id="ref75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gilhooley</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hankins</surname><given-names>M. W.</given-names></name></person-group> (<year>2022</year>). <article-title>Optogenetics for visual restoration: from proof of principle to translational challenges</article-title>. <source>Prog. Retin. Eye Res.</source><volume>91</volume>:<fpage>101089</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.preteyeres.2022.101089</pub-id>, PMID: <pub-id pub-id-type="pmid">35691861</pub-id></mixed-citation></ref><ref id="ref76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lor&#233;s-Motta</surname><given-names>L.</given-names></name><name name-style="western"><surname>Paun</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Corominas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pauper</surname><given-names>M.</given-names></name><name name-style="western"><surname>Geerlings</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Altay</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Genome-wide association study reveals variants in CFH and CFHR4 associated with systemic complement activation</article-title>. <source>Ophthalmology</source><volume>125</volume>, <fpage>1064</fpage>&#8211;<lpage>1074</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ophtha.2017.12.023</pub-id>, PMID: <pub-id pub-id-type="pmid">29398083</pub-id></mixed-citation></ref><ref id="ref77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>Y. H.-L.</given-names></name><name name-style="western"><surname>da Cruz</surname><given-names>L.</given-names></name></person-group> (<year>2016</year>). <article-title>The Argus&#174; II retinal prosthesis system</article-title>. <source>Prog. Retin. Eye Res.</source><volume>50</volume>, <fpage>89</fpage>&#8211;<lpage>107</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.preteyeres.2015.09.003</pub-id><pub-id pub-id-type="pmid">26404104</pub-id></mixed-citation></ref><ref id="ref78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maisonpierre</surname><given-names>P. C.</given-names></name><name name-style="western"><surname>Suri</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>P. F.</given-names></name><name name-style="western"><surname>Bartunkova</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wiegand</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Radziejewski</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>1997</year>). <article-title>Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis</article-title>. <source>Science</source><volume>277</volume>, <fpage>55</fpage>&#8211;<lpage>60</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.277.5322.55</pub-id>, PMID: <pub-id pub-id-type="pmid">9204896</pub-id></mixed-citation></ref><ref id="ref79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Margolis</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Detwiler</surname><given-names>P. B.</given-names></name></person-group> (<year>2011</year>). <article-title>Cellular origin of spontaneous ganglion cell spike activity in animal models of retinitis pigmentosa</article-title>. <source>J. Ophthalmol.</source><volume>2011</volume>:<fpage>507037</fpage>.<pub-id pub-id-type="pmid">20936060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2011/507037</pub-id><pub-id pub-id-type="pmcid">PMC2948917</pub-id></mixed-citation></ref><ref id="ref80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGregor</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Godat</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dhakal</surname><given-names>K. R.</given-names></name><name name-style="western"><surname>Parkins</surname><given-names>K.</given-names></name><name name-style="western"><surname>Strazzeri</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Bateman</surname><given-names>B. A.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Optogenetic restoration of retinal ganglion cell activity in the living primate</article-title>. <source>Nat. Commun.</source><volume>11</volume>:<fpage>1703</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41467-020-15317-6</pub-id>, PMID: <pub-id pub-id-type="pmid">32245977</pub-id><pub-id pub-id-type="pmcid">PMC7125151</pub-id></mixed-citation></ref><ref id="ref81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merle</surname><given-names>N. S.</given-names></name><name name-style="western"><surname>Church</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Fremeaux-Bacchi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Roumenina</surname><given-names>L. T.</given-names></name></person-group> (<year>2015</year>). <article-title>Complement system part I - molecular mechanisms of activation and regulation</article-title>. <source>Front. Immunol.</source><volume>6</volume>:<fpage>262</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2015.00262</pub-id><pub-id pub-id-type="pmid">26082779</pub-id><pub-id pub-id-type="pmcid">PMC4451739</pub-id></mixed-citation></ref><ref id="ref82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michael</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>E. L.</given-names></name></person-group> (<year>2004</year>). <article-title>Retinitis pigmentosa: understanding the clinical presentation, mechanisms and treatment options</article-title>. <source>Clin. Exp. Optometry</source><volume>87</volume>, <fpage>65</fpage>&#8211;<lpage>80</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1444-0938.2004.tb03152.x</pub-id><pub-id pub-id-type="pmid">15040773</pub-id></mixed-citation></ref><ref id="ref83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreno-Garc&#237;a</surname><given-names>A.</given-names></name><name name-style="western"><surname>Medina</surname><given-names>M.</given-names></name><name name-style="western"><surname>Calero</surname><given-names>M.</given-names></name></person-group> (<year>2018</year>). <article-title>An overview of the role of lipofuscin in age-related neurodegeneration</article-title>. <source>Front. Neurosci.</source><volume>12</volume>:<fpage>464</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnins.2018.00464</pub-id>, PMID: <pub-id pub-id-type="pmid">30026686</pub-id><pub-id pub-id-type="pmcid">PMC6041410</pub-id></mixed-citation></ref><ref id="ref84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mousavi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>R. A.</given-names></name></person-group> (<year>2013</year>). <article-title>Genetic risk factors and age-related macular degeneration (AMD)</article-title>. <source>J. Optom.</source><volume>6</volume>, <fpage>176</fpage>&#8211;<lpage>184</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.optom.2013.07.002</pub-id><pub-id pub-id-type="pmid">27125062</pub-id></mixed-citation></ref><ref id="ref85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kiss</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sulzbacher</surname><given-names>F.</given-names></name><name name-style="western"><surname>Eisenk&#246;lbl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sacu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kalcher</surname><given-names>K.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Short-term progression of wet AMD and correlation with 1-year treatment results</article-title>. <source>Acta Ophthalmol.</source><volume>90</volume>, <fpage>e420</fpage>&#8211;<lpage>e427</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1755-3768.2011.02353.x</pub-id>, PMID: <pub-id pub-id-type="pmid">22339794</pub-id></mixed-citation></ref><ref id="ref86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muqit</surname><given-names>M. M. K.</given-names></name><name name-style="western"><surname>le Mer</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Olmos de Koo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Holz</surname><given-names>F. G.</given-names></name><name name-style="western"><surname>Sahel</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Palanker</surname><given-names>D.</given-names></name></person-group> (<year>2024</year>). <article-title>Prosthetic visual acuity with the PRIMA subretinal microchip in patients with atrophic age-related macular degeneration at 4 years follow-up</article-title>. <source>Ophthalmol. Sci.</source><volume>4</volume>:<fpage>100510</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.xops.2024.100510</pub-id>, PMID: <pub-id pub-id-type="pmid">38881600</pub-id><pub-id pub-id-type="pmcid">PMC11179408</pub-id></mixed-citation></ref><ref id="ref87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>G. J.</given-names></name><name name-style="western"><surname>Rieke</surname><given-names>F.</given-names></name></person-group> (<year>2008</year>). <article-title>Signals and noise in an inhibitory interneuron diverge to control activity in nearby retinal ganglion cells</article-title>. <source>Nat. Neurosci.</source><volume>11</volume>, <fpage>318</fpage>&#8211;<lpage>326</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nn2045</pub-id>, PMID: <pub-id pub-id-type="pmid">18223648</pub-id><pub-id pub-id-type="pmcid">PMC2279192</pub-id></mixed-citation></ref><ref id="ref88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sch&#246;nfisch</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zrenner</surname><given-names>E.</given-names></name><name name-style="western"><surname>J&#228;gle</surname><given-names>H.</given-names></name></person-group> (<year>2008</year>). <article-title>Long-term follow-up of retinitis Pigmentosa patients with multifocal electroretinography</article-title>. <source>Invest. Ophthalmol. Vis. Sci.</source><volume>49</volume>, <fpage>4664</fpage>&#8211;<lpage>4671</lpage>. doi: <pub-id pub-id-type="doi">10.1167/iovs.07-1360</pub-id>, PMID: <pub-id pub-id-type="pmid">18566474</pub-id></mixed-citation></ref><ref id="ref89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nebbioso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barbato</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pescosolido</surname><given-names>N.</given-names></name></person-group> (<year>2014</year>). <article-title>Scotopic Microperimetry in the early diagnosis of age-related macular degeneration: preliminary study</article-title>. <source>Biomed Res Int.</source><volume>2014</volume>:<fpage>671529</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2014/671529</pub-id><pub-id pub-id-type="pmid">25548774</pub-id><pub-id pub-id-type="pmcid">PMC4274674</pub-id></mixed-citation></ref><ref id="ref90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Newton</surname><given-names>F.</given-names></name><name name-style="western"><surname>Megaw</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>Mechanisms of photoreceptor death in retinitis Pigmentosa</article-title>. <source>Genes</source><volume>11</volume>:<fpage>1120</fpage>. doi: <pub-id pub-id-type="doi">10.3390/genes11101120</pub-id>, PMID: <pub-id pub-id-type="pmid">32987769</pub-id><pub-id pub-id-type="pmcid">PMC7598671</pub-id></mixed-citation></ref><ref id="ref91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ng</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Yip</surname><given-names>Y. W.</given-names></name><name name-style="western"><surname>Bakthavatsalam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L. J.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>T. K.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>T. Y.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Elevated angiopoietin 2 in aqueous of patients with neovascular age related macular degeneration correlates with disease severity at presentation</article-title>. <source>Sci. Rep.</source><volume>7</volume>:<fpage>45081</fpage>. doi: <pub-id pub-id-type="doi">10.1038/srep45081</pub-id>, PMID: <pub-id pub-id-type="pmid">28345626</pub-id><pub-id pub-id-type="pmcid">PMC5366858</pub-id></mixed-citation></ref><ref id="ref92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nigalye</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Hess</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pundlik</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Jeffrey</surname><given-names>B. G.</given-names></name><name name-style="western"><surname>Cukras</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Husain</surname><given-names>D.</given-names></name></person-group> (<year>2022</year>). <article-title>Dark adaptation and its role in age-related macular degeneration</article-title>. <source>J. Clin. Med.</source><volume>11</volume>:<fpage>1358</fpage>. doi: <pub-id pub-id-type="doi">10.3390/jcm11051358</pub-id>, PMID: <pub-id pub-id-type="pmid">35268448</pub-id><pub-id pub-id-type="pmcid">PMC8911214</pub-id></mixed-citation></ref><ref id="ref93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Otsuka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Oishi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Miyata</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oishi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Numa</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Wavelength of light and photophobia in inherited retinal dystrophy</article-title>. <source>Sci. Rep.</source><volume>10</volume>:<fpage>14798</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-020-71707-2</pub-id>, PMID: <pub-id pub-id-type="pmid">32908200</pub-id><pub-id pub-id-type="pmcid">PMC7481180</pub-id></mixed-citation></ref><ref id="ref94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Owsley</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huisingh</surname><given-names>C.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>G. R.</given-names></name><name name-style="western"><surname>McGwin</surname><given-names>G.</given-names><suffix>Jr.</suffix></name></person-group> (<year>2016</year>). <article-title>Comparison of visual function in older eyes in the earliest stages of age-related macular degeneration to those in Normal macular health</article-title>. <source>Curr. Eye Res.</source><volume>41</volume>, <fpage>266</fpage>&#8211;<lpage>272</lpage>. doi: <pub-id pub-id-type="doi">10.3109/02713683.2015.1011282</pub-id>, PMID: <pub-id pub-id-type="pmid">25802989</pub-id><pub-id pub-id-type="pmcid">PMC4737986</pub-id></mixed-citation></ref><ref id="ref95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#214;zg&#252;l</surname><given-names>R. K.</given-names></name><name name-style="western"><surname>Siemiatkowska</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Y&#252;cel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Myers</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Collin</surname><given-names>R. W.</given-names></name><name name-style="western"><surname>Zonneveld</surname><given-names>M. N.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Exome sequencing and cis-regulatory mapping identify mutations in MAK, a gene encoding a regulator of ciliary length, as a cause of retinitis Pigmentosa</article-title>. <source>Am. J. Hum. Genet.</source><volume>89</volume>, <fpage>253</fpage>&#8211;<lpage>264</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ajhg.2011.07.005</pub-id>, PMID: <pub-id pub-id-type="pmid">21835304</pub-id><pub-id pub-id-type="pmcid">PMC3155188</pub-id></mixed-citation></ref><ref id="ref96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palanker</surname><given-names>D. V.</given-names></name></person-group> (<year>2021</year>). <article-title>Simultaneous perception of prosthetic and natural vision in patients with geographic atrophy</article-title>. <source>Invest. Ophthalmol. Vis. Sci.</source><volume>62</volume>:<fpage>3556</fpage>.</mixed-citation></ref><ref id="ref97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pang</surname><given-names>J.-J.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S. M.</given-names></name></person-group> (<year>2003</year>). <article-title>Light-evoked excitatory and inhibitory synaptic inputs to ON and OFF &#945; ganglion cells in the mouse retina</article-title>. <source>J. Neurosci.</source><volume>23</volume>, <fpage>6063</fpage>&#8211;<lpage>6073</lpage>. doi: <pub-id pub-id-type="doi">10.1523/JNEUROSCI.23-14-06063.2003</pub-id>, PMID: <pub-id pub-id-type="pmid">12853425</pub-id><pub-id pub-id-type="pmcid">PMC6740343</pub-id></mixed-citation></ref><ref id="ref98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parente</surname><given-names>R.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Inforzato</surname><given-names>A.</given-names></name><name name-style="western"><surname>Day</surname><given-names>A. J.</given-names></name></person-group> (<year>2017</year>). <article-title>Complement factor H in host defense and immune evasion</article-title>. <source>Cell. Mol. Life Sci.</source><volume>74</volume>, <fpage>1605</fpage>&#8211;<lpage>1624</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00018-016-2418-4</pub-id>, PMID: <pub-id pub-id-type="pmid">27942748</pub-id><pub-id pub-id-type="pmcid">PMC5378756</pub-id></mixed-citation></ref><ref id="ref99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>Y.-W.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Petters</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>F.</given-names></name></person-group> (<year>2000</year>). <article-title>Ectopic synaptogenesis in the mammalian retina caused by rod photoreceptor-specific mutations</article-title>. <source>Nat. Neurosci.</source><volume>3</volume>, <fpage>1121</fpage>&#8211;<lpage>1127</lpage>. doi: <pub-id pub-id-type="doi">10.1038/80639</pub-id>, PMID: <pub-id pub-id-type="pmid">11036269</pub-id></mixed-citation></ref><ref id="ref100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pennesi</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Neuringer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Courtney</surname><given-names>R. J.</given-names></name></person-group> (<year>2012</year>). <article-title>Animal models of age related macular degeneration</article-title>. <source>Mol. Asp. Med.</source><volume>33</volume>, <fpage>487</fpage>&#8211;<lpage>509</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.mam.2012.06.003</pub-id>, PMID: <pub-id pub-id-type="pmid">22705444</pub-id><pub-id pub-id-type="pmcid">PMC3770531</pub-id></mixed-citation></ref><ref id="ref101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phelan</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Bok</surname><given-names>D.</given-names></name></person-group> (<year>2000</year>) <article-title>A brief review of retinitis pigmentosa and the identified retinitis pigmentosa genes</article-title>. <source>Mol. Vis.</source><volume>6</volume>, <fpage>116</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">10889272</pub-id></mixed-citation></ref><ref id="ref102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phillips</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Otteson</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Sherry</surname><given-names>D. M.</given-names></name></person-group> (<year>2010</year>). <article-title>Progression of neuronal and synaptic remodeling in the rd10 mouse model of retinitis pigmentosa</article-title>. <source>J. Comp. Neurol.</source><volume>518</volume>, <fpage>2071</fpage>&#8211;<lpage>2089</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cne.22322</pub-id>, PMID: <pub-id pub-id-type="pmid">20394059</pub-id><pub-id pub-id-type="pmcid">PMC2881548</pub-id></mixed-citation></ref><ref id="ref103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pieramici</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Rabena</surname><given-names>M. D.</given-names></name></person-group> (<year>2008</year>). <article-title>Anti-VEGF therapy: comparison of current and future agents</article-title>. <source>Eye</source><volume>22</volume>, <fpage>1330</fpage>&#8211;<lpage>1336</lpage>. doi: <pub-id pub-id-type="doi">10.1038/eye.2008.88</pub-id>, PMID: <pub-id pub-id-type="pmid">18497829</pub-id></mixed-citation></ref><ref id="ref104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pierrottet</surname><given-names>C. O.</given-names></name><name name-style="western"><surname>Zuntini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Digiuni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bazzanella</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ferri</surname><given-names>P.</given-names></name><name name-style="western"><surname>Paderni</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Syndromic and non-syndromic forms of retinitis pigmentosa: a comprehensive Italian clinical and molecular study reveals new mutations</article-title>. <source>Genet. Mol. Res.</source><volume>13</volume>, <fpage>8815</fpage>&#8211;<lpage>8833</lpage>. doi: <pub-id pub-id-type="doi">10.4238/2014.October.27.23</pub-id><pub-id pub-id-type="pmid">25366773</pub-id></mixed-citation></ref><ref id="ref105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pondorfer</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Terheyden</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Heinemann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wintergerst</surname><given-names>M. W. M.</given-names></name><name name-style="western"><surname>Holz</surname><given-names>F. G.</given-names></name><name name-style="western"><surname>Finger</surname><given-names>R. P.</given-names></name></person-group> (<year>2019</year>). <article-title>Association of Vision-related Quality of life with visual function in age-related macular degeneration</article-title>. <source>Sci. Rep.</source><volume>9</volume>:<fpage>15326</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-019-51769-7</pub-id>, PMID: <pub-id pub-id-type="pmid">31653904</pub-id><pub-id pub-id-type="pmcid">PMC6814705</pub-id></mixed-citation></ref><ref id="ref106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pugazhendhi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hubbell</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jairam</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ambati</surname><given-names>B.</given-names></name></person-group> (<year>2021</year>). <article-title>Neovascular macular degeneration: a review of etiology, risk factors, and recent advances in research and therapy</article-title>. <source>Int. J. Mol. Sci.</source><volume>22</volume>:<fpage>1170</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms22031170</pub-id><pub-id pub-id-type="pmid">33504013</pub-id><pub-id pub-id-type="pmcid">PMC7866170</pub-id></mixed-citation></ref><ref id="ref107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Punzo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kornacker</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cepko</surname><given-names>C. L.</given-names></name></person-group> (<year>2009</year>). <article-title>Stimulation of the insulin/mTOR pathway delays cone death in a mouse model of retinitis pigmentosa</article-title>. <source>Nat. Neurosci.</source><volume>12</volume>, <fpage>44</fpage>&#8211;<lpage>52</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nn.2234</pub-id>, PMID: <pub-id pub-id-type="pmid">19060896</pub-id><pub-id pub-id-type="pmcid">PMC3339764</pub-id></mixed-citation></ref><ref id="ref108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puthussery</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gayet-Primo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>S.</given-names></name><name name-style="western"><surname>Duvoisin</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>W. R.</given-names></name></person-group> (<year>2009</year>). <article-title>Differential loss and preservation of glutamate receptor function in bipolar cells in the rd10 mouse model of retinitis pigmentosa</article-title>. <source>Eur. J. Neurosci.</source><volume>29</volume>, <fpage>1533</fpage>&#8211;<lpage>1542</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1460-9568.2009.06728.x</pub-id>, PMID: <pub-id pub-id-type="pmid">19385989</pub-id><pub-id pub-id-type="pmcid">PMC2818147</pub-id></mixed-citation></ref><ref id="ref109"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Puthussery</surname><given-names>T.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>W. R.</given-names></name></person-group> (<year>2010</year>). &#8220;<article-title>Functional changes in inner retinal neurons in animal models of photoreceptor degeneration</article-title>&#8221; in <source>Retinal degenerative diseases: Laboratory and therapeutic investigations</source>. eds. <person-group person-group-type="editor"><name name-style="western"><surname>Anderson</surname><given-names>R. E.</given-names></name><name name-style="western"><surname>Hollyfield</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>LaVail</surname><given-names>M. M.</given-names></name></person-group> (<publisher-loc>New York, NY</publisher-loc>: <publisher-name>Springer</publisher-name>), <fpage>525</fpage>&#8211;<lpage>532</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-4419-1399-9_60</pub-id><pub-id pub-id-type="pmid">20238055</pub-id></mixed-citation></ref><ref id="ref110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajanala</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dotiwala</surname><given-names>F.</given-names></name><name name-style="western"><surname>Upadhyay</surname><given-names>A.</given-names></name></person-group> (<year>2023</year>). <article-title>Geographic atrophy: pathophysiology and current therapeutic strategies</article-title>. <source>Front. Ophthalmol.</source><volume>3</volume>:<fpage>1327883</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fopht.2023.1327883</pub-id>, PMID: <pub-id pub-id-type="pmid">38983017</pub-id><pub-id pub-id-type="pmcid">PMC11182118</pub-id></mixed-citation></ref><ref id="ref111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramirez</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Drew-Bear</surname><given-names>L. E.</given-names></name><name name-style="western"><surname>Vega-Garces</surname><given-names>M.</given-names></name><name name-style="western"><surname>Betancourt-Belandria</surname><given-names>H.</given-names></name><name name-style="western"><surname>Arevalo</surname><given-names>J. F.</given-names></name></person-group> (<year>2023</year>). <article-title>An update on visual prosthesis</article-title>. <source>Int. J. Retina Vitr.</source><volume>9</volume>:<fpage>73</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s40942-023-00498-1</pub-id>, PMID: <pub-id pub-id-type="pmid">37996905</pub-id><pub-id pub-id-type="pmcid">PMC10668475</pub-id></mixed-citation></ref><ref id="ref112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reiter</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Leroux</surname><given-names>M. R.</given-names></name></person-group> (<year>2017</year>). <article-title>Genes and molecular pathways underpinning ciliopathies</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source><volume>18</volume>, <fpage>533</fpage>&#8211;<lpage>547</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrm.2017.60</pub-id>, PMID: <pub-id pub-id-type="pmid">28698599</pub-id><pub-id pub-id-type="pmcid">PMC5851292</pub-id></mixed-citation></ref><ref id="ref113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossino</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Lulli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Amato</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cammalleri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Monte</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Casini</surname><given-names>G.</given-names></name></person-group> (<year>2020</year>). <article-title>Oxidative Stress Induces a VEGF Autocrine Loop in the Retina: Relevance for Diabetic Retinopathy</article-title>. <source>Cells</source><volume>9</volume>:<fpage>1452</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells9061452</pub-id><pub-id pub-id-type="pmid">32545222</pub-id><pub-id pub-id-type="pmcid">PMC7349409</pub-id></mixed-citation></ref><ref id="ref114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seddon</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>R.</given-names></name><name name-style="western"><surname>Maller</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fagerness</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Daly</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Rosner</surname><given-names>B.</given-names></name></person-group> (<year>2009</year>). <article-title>Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables</article-title>. <source>Invest. Ophthalmol. Vis. Sci.</source><volume>50</volume>, <fpage>2044</fpage>&#8211;<lpage>2053</lpage>. doi: <pub-id pub-id-type="doi">10.1167/iovs.08-3064</pub-id><pub-id pub-id-type="pmid">19117936</pub-id><pub-id pub-id-type="pmcid">PMC3772781</pub-id></mixed-citation></ref><ref id="ref115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaw</surname><given-names>P. X.</given-names></name><name name-style="western"><surname>Stiles</surname><given-names>T.</given-names></name><name name-style="western"><surname>Douglas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Du</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Oxidative stress, innate immunity, and age-related macular degeneration</article-title>. <source>AIMS Mol. Sci.</source><volume>3</volume>, <fpage>196</fpage>&#8211;<lpage>221</lpage>. doi: <pub-id pub-id-type="doi">10.3934/molsci.2016.2.196</pub-id>, PMID: <pub-id pub-id-type="pmid">27239555</pub-id><pub-id pub-id-type="pmcid">PMC4882104</pub-id></mixed-citation></ref><ref id="ref116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaw</surname><given-names>P. X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Du</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C.</given-names></name></person-group> (<year>2012</year>). <article-title>Complement factor H genotypes impact risk of age-related macular degeneration by interaction with oxidized phospholipids</article-title>. <source>Proc. Natl. Acad. Sci. USA</source><volume>109</volume>, <fpage>13757</fpage>&#8211;<lpage>13762</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1121309109</pub-id><pub-id pub-id-type="pmid">22875704</pub-id><pub-id pub-id-type="pmcid">PMC3427125</pub-id></mixed-citation></ref><ref id="ref117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>A.</given-names></name><name name-style="western"><surname>Petters</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y. W.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>2005</year>). <article-title>Oxidative damage is a potential cause of cone cell death in retinitis pigmentosa</article-title>. <source>J. Cell. Physiol.</source><volume>203</volume>, <fpage>457</fpage>&#8211;<lpage>464</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jcp.20346</pub-id>, PMID: <pub-id pub-id-type="pmid">15744744</pub-id></mixed-citation></ref><ref id="ref118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simunovic</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Protti</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Lisowski</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gillies</surname><given-names>M. C.</given-names></name></person-group> (<year>2019</year>). <article-title>Optogenetic approaches to vision restoration</article-title>. <source>Exp. Eye Res.</source><volume>178</volume>, <fpage>15</fpage>&#8211;<lpage>26</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.exer.2018.09.003</pub-id><pub-id pub-id-type="pmid">30218651</pub-id></mixed-citation></ref><ref id="ref119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>W.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>P.</given-names></name><name name-style="western"><surname>Leeder</surname><given-names>S. R.</given-names></name></person-group> (<year>1996</year>). <article-title>Smoking and age-related maculopathy: the Blue Mountains eye study</article-title>. <source>Arch. Ophthalmol.</source><volume>114</volume>, <fpage>1518</fpage>&#8211;<lpage>1523</lpage>. doi: <pub-id pub-id-type="doi">10.1001/archopht.1996.01100140716016</pub-id><pub-id pub-id-type="pmid">8953988</pub-id></mixed-citation></ref><ref id="ref120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Storti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Raphael</surname><given-names>G.</given-names></name><name name-style="western"><surname>Griesser</surname><given-names>V.</given-names></name><name name-style="western"><surname>Klee</surname><given-names>K.</given-names></name><name name-style="western"><surname>Drawnel</surname><given-names>F.</given-names></name><name name-style="western"><surname>Willburger</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Regulated efflux of photoreceptor outer segment-derived cholesterol by human RPE cells</article-title>. <source>Exp. Eye Res.</source><volume>165</volume>, <fpage>65</fpage>&#8211;<lpage>77</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.exer.2017.09.008</pub-id><pub-id pub-id-type="pmid">28943268</pub-id></mixed-citation></ref><ref id="ref121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sullivan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Penfold</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pow</surname><given-names>D. V.</given-names></name></person-group> (<year>2003</year>). <article-title>Neuronal migration and glial remodeling in degenerating retinas of aged rats and in Nonneovascular AMD</article-title>. <source>Invest. Ophthalmol. Vis. Sci.</source><volume>44</volume>, <fpage>856</fpage>&#8211;<lpage>865</lpage>. doi: <pub-id pub-id-type="doi">10.1167/iovs.02-0416</pub-id>, PMID: <pub-id pub-id-type="pmid">12556422</pub-id></mixed-citation></ref><ref id="ref122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>H. R.</given-names></name><name name-style="western"><surname>West</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mu&#241;oz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>F. S.</given-names></name><name name-style="western"><surname>Bressler</surname><given-names>S. B.</given-names></name><name name-style="western"><surname>Bressler</surname><given-names>N. M.</given-names></name></person-group> (<year>1992</year>). <article-title>The long-term effects of visible light on the eye</article-title>. <source>Arch. Ophthalmol.</source><volume>110</volume>, <fpage>99</fpage>&#8211;<lpage>104</lpage>. doi: <pub-id pub-id-type="doi">10.1001/archopht.1992.01080130101035</pub-id><pub-id pub-id-type="pmid">1731731</pub-id></mixed-citation></ref><ref id="ref123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Telias</surname><given-names>M.</given-names></name><name name-style="western"><surname>Denlinger</surname><given-names>B.</given-names></name><name name-style="western"><surname>Helft</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Thornton</surname><given-names>C.</given-names></name><name name-style="western"><surname>Beckwith-Cohen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>R. H.</given-names></name></person-group> (<year>2019</year>). <article-title>Retinoic acid induces hyperactivity, and blocking its receptor unmasks light responses and augments vision in retinal degeneration</article-title>. <source>Neuron</source><volume>102</volume>, <fpage>574</fpage>&#8211;<lpage>586.e5</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuron.2019.02.015</pub-id><pub-id pub-id-type="pmid">30876849</pub-id><pub-id pub-id-type="pmcid">PMC6508985</pub-id></mixed-citation></ref><ref id="ref124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trenholm</surname><given-names>S.</given-names></name><name name-style="western"><surname>Awatramani</surname><given-names>G. B.</given-names></name></person-group> (<year>2015</year>). <article-title>Origins of spontaneous activity in the degenerating retina</article-title>. <source>Front. Cell. Neurosci.</source><volume>9</volume>:<fpage>277</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fncel.2015.00277</pub-id>, PMID: <pub-id pub-id-type="pmid">26283914</pub-id><pub-id pub-id-type="pmcid">PMC4518194</pub-id></mixed-citation></ref><ref id="ref125"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Tsang</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Aycinena</surname><given-names>A. R. P.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>T.</given-names></name></person-group><article-title>Ciliopathy: usher syndrome</article-title>. in <source>Atlas of inherited retinal diseases</source> (eds. <person-group person-group-type="editor"><name name-style="western"><surname>Tsang</surname><given-names>S. H.</given-names></name></person-group> &amp; <person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>T.</given-names></name></person-group>.) <fpage>167</fpage>&#8211;<lpage>170</lpage><publisher-loc>Cham</publisher-loc>: <publisher-name>Springer International Publishing</publisher-name> (<year>2018</year>).</mixed-citation></ref><ref id="ref126"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsujikawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wada</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sukegawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gomi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nishida</surname><given-names>K.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>Age at onset curves of retinitis Pigmentosa</article-title>. <source>Arch. Ophthalmol.</source><volume>126</volume>, <fpage>337</fpage>&#8211;<lpage>340</lpage>. doi: <pub-id pub-id-type="doi">10.1001/archopht.126.3.337</pub-id>, PMID: <pub-id pub-id-type="pmid">18332312</pub-id></mixed-citation></ref><ref id="ref127"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaidya</surname><given-names>A.</given-names></name><name name-style="western"><surname>Borgonovi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Sahel</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Rizzo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stanga</surname><given-names>P. E.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>The cost-effectiveness of the Argus II retinal prosthesis in retinitis Pigmentosa patients</article-title>. <source>BMC Ophthalmol.</source><volume>14</volume>:<fpage>49</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1471-2415-14-49</pub-id>, PMID: <pub-id pub-id-type="pmid">24731533</pub-id><pub-id pub-id-type="pmcid">PMC3990272</pub-id></mixed-citation></ref><ref id="ref128"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Soest</surname><given-names>S.</given-names></name><name name-style="western"><surname>Westerveld</surname><given-names>A.</given-names></name><name name-style="western"><surname>De Jong</surname><given-names>P. T. V. M.</given-names></name><name name-style="western"><surname>Bleeker-Wagemakers</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Bergen</surname><given-names>A. A. B.</given-names></name></person-group> (<year>1999</year>). <article-title>Retinitis Pigmentosa: defined from a molecular point of view</article-title>. <source>Surv. Ophthalmol.</source><volume>43</volume>, <fpage>321</fpage>&#8211;<lpage>334</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0039-6257(98)00046-0</pub-id>, PMID: <pub-id pub-id-type="pmid">10025514</pub-id></mixed-citation></ref><ref id="ref129"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verbakel</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>van Huet</surname><given-names>R. A. C.</given-names></name><name name-style="western"><surname>Boon</surname><given-names>C. J. F.</given-names></name><name name-style="western"><surname>den Hollander</surname><given-names>A. I.</given-names></name><name name-style="western"><surname>Collin</surname><given-names>R. W. J.</given-names></name><name name-style="western"><surname>Klaver</surname><given-names>C. C. W.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Non-syndromic retinitis pigmentosa</article-title>. <source>Prog. Retin. Eye Res.</source><volume>66</volume>, <fpage>157</fpage>&#8211;<lpage>186</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.preteyeres.2018.03.005</pub-id><pub-id pub-id-type="pmid">29597005</pub-id></mixed-citation></ref><ref id="ref130"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Salem</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Oliver</surname><given-names>Z. T.</given-names></name><name name-style="western"><surname>Clark-Sutton</surname><given-names>K.</given-names></name></person-group> (<year>2018</year>). <article-title>Social and economic impact of the commercialization of the Argus II artificial retina in the United States</article-title>. <source>J. Technol. Transf.</source><volume>43</volume>, <fpage>1607</fpage>&#8211;<lpage>1630</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10961-017-9610-z</pub-id></mixed-citation></ref><ref id="ref131"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Lukas</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>M.</given-names></name><name name-style="western"><surname>du</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tso</surname><given-names>M. O.</given-names></name><name name-style="western"><surname>Neufeld</surname><given-names>A. H.</given-names></name></person-group> (<year>2009</year>). <article-title>Autophagy and exosomes in the aged retinal pigment epithelium: possible relevance to Drusen formation and age-related macular degeneration</article-title>. <source>PLoS One</source><volume>4</volume>:<fpage>e4160</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0004160</pub-id><pub-id pub-id-type="pmid">19129916</pub-id><pub-id pub-id-type="pmcid">PMC2612751</pub-id></mixed-citation></ref><ref id="ref132"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>V. M.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>C.-C.</given-names></name></person-group> (<year>2011</year>). <article-title>The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment</article-title>. <source>Eye</source><volume>25</volume>, <fpage>127</fpage>&#8211;<lpage>139</lpage>. doi: <pub-id pub-id-type="doi">10.1038/eye.2010.196</pub-id>, PMID: <pub-id pub-id-type="pmid">21183941</pub-id><pub-id pub-id-type="pmcid">PMC3044916</pub-id></mixed-citation></ref><ref id="ref133"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waters</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Beales</surname><given-names>P. L.</given-names></name></person-group> (<year>2011</year>). <article-title>Ciliopathies: an expanding disease spectrum</article-title>. <source>Pediatr. Nephrol.</source><volume>26</volume>, <fpage>1039</fpage>&#8211;<lpage>1056</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00467-010-1731-7</pub-id>, PMID: <pub-id pub-id-type="pmid">21210154</pub-id><pub-id pub-id-type="pmcid">PMC3098370</pub-id></mixed-citation></ref><ref id="ref134"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Lopes</surname><given-names>V. S.</given-names></name></person-group> (<year>2011</year>). <article-title>The many different cellular functions of MYO7A in the retina</article-title>. <source>Biochem. Soc. Trans.</source><volume>39</volume>, <fpage>1207</fpage>&#8211;<lpage>1210</lpage>. doi: <pub-id pub-id-type="doi">10.1042/BST0391207</pub-id>, PMID: <pub-id pub-id-type="pmid">21936790</pub-id><pub-id pub-id-type="pmcid">PMC3703834</pub-id></mixed-citation></ref><ref id="ref135"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>W. L.</given-names></name><name name-style="western"><surname>Su</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>C. M. G.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>C. Y.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis</article-title>. <source>Lancet Glob. Health</source><volume>2</volume>, <fpage>e106</fpage>&#8211;<lpage>e116</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S2214-109X(13)70145-1</pub-id>, PMID: <pub-id pub-id-type="pmid">25104651</pub-id></mixed-citation></ref><ref id="ref136"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wood</surname><given-names>E. H.</given-names></name><name name-style="western"><surname>Kreymerman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kowal</surname><given-names>T.</given-names></name><name name-style="western"><surname>Buickians</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Muscat</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Cellular and subcellular optogenetic approaches towards neuroprotection and vision restoration</article-title>. <source>Prog. Retin. Eye Res.</source><volume>96</volume>:<fpage>101153</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.preteyeres.2022.101153</pub-id>, PMID: <pub-id pub-id-type="pmid">36503723</pub-id><pub-id pub-id-type="pmcid">PMC10247900</pub-id></mixed-citation></ref><ref id="ref137"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>K. Y.</given-names></name><name name-style="western"><surname>Kulbay</surname><given-names>M.</given-names></name><name name-style="western"><surname>Toameh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>A. Q.</given-names></name><name name-style="western"><surname>Kalevar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>S. D.</given-names></name></person-group> (<year>2023</year>). <article-title>Retinitis Pigmentosa: novel therapeutic targets and drug development</article-title>. <source>Pharmaceutics</source><volume>15</volume>:<fpage>685</fpage>. doi: <pub-id pub-id-type="doi">10.3390/pharmaceutics15020685</pub-id>, PMID: <pub-id pub-id-type="pmid">36840007</pub-id><pub-id pub-id-type="pmcid">PMC9963330</pub-id></mixed-citation></ref><ref id="ref138"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mohand-Said</surname><given-names>S.</given-names></name><name name-style="western"><surname>Danan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Simonutti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fontaine</surname><given-names>V.</given-names></name><name name-style="western"><surname>Clerin</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Functional cone rescue by RdCVF protein in a dominant model of retinitis Pigmentosa</article-title>. <source>Mol. Ther.</source><volume>17</volume>, <fpage>787</fpage>&#8211;<lpage>795</lpage>. doi: <pub-id pub-id-type="doi">10.1038/mt.2009.28</pub-id>, PMID: <pub-id pub-id-type="pmid">19277021</pub-id><pub-id pub-id-type="pmcid">PMC2835133</pub-id></mixed-citation></ref><ref id="ref139"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Goo</surname><given-names>Y. S.</given-names></name></person-group> (<year>2007</year>). <article-title>The slow wave component of retinal activity in rd/rd mice recorded with a multi-electrode array</article-title>. <source>Physiol. Meas.</source><volume>28</volume>, <fpage>1079</fpage>&#8211;<lpage>1088</lpage>. doi: <pub-id pub-id-type="doi">10.1088/0967-3334/28/9/009</pub-id><pub-id pub-id-type="pmid">17827655</pub-id></mixed-citation></ref><ref id="ref140"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yonekawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>I. K.</given-names></name></person-group> (<year>2015</year>). <article-title>Clinical characteristics and current treatment of age-related macular degeneration</article-title>. <source>Cold Spring Harb. Perspect. Med.</source><volume>5</volume>:<fpage>a017178</fpage>. doi: <pub-id pub-id-type="doi">10.1101/cshperspect.a017178</pub-id>, PMID: <pub-id pub-id-type="pmid">25280900</pub-id><pub-id pub-id-type="pmcid">PMC4292078</pub-id></mixed-citation></ref><ref id="ref141"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>R. W.</given-names></name></person-group> (<year>1971</year>). <article-title>The renewal of rod and cone outer segments in the RHESUS monkey</article-title>. <source>J. Cell Biol.</source><volume>49</volume>, <fpage>303</fpage>&#8211;<lpage>318</lpage>. doi: <pub-id pub-id-type="doi">10.1083/jcb.49.2.303</pub-id>, PMID: <pub-id pub-id-type="pmid">19866760</pub-id><pub-id pub-id-type="pmcid">PMC2108322</pub-id></mixed-citation></ref><ref id="ref142"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>R. W.</given-names></name><name name-style="western"><surname>Bok</surname><given-names>D.</given-names></name></person-group> (<year>1969</year>). <article-title>Participation of the retinal pigment epithelium in the rod outer segment renewal process</article-title>. <source>J. Cell Biol.</source><volume>42</volume>, <fpage>392</fpage>&#8211;<lpage>403</lpage>. doi: <pub-id pub-id-type="doi">10.1083/jcb.42.2.392</pub-id>, PMID: <pub-id pub-id-type="pmid">5792328</pub-id><pub-id pub-id-type="pmcid">PMC2107669</pub-id></mixed-citation></ref><ref id="ref143"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>D.-Y.</given-names></name><name name-style="western"><surname>Cringle</surname><given-names>S. J.</given-names></name></person-group> (<year>2001</year>). <article-title>Oxygen distribution and consumption within the retina in vascularised and avascular retinas and in animal models of retinal disease</article-title>. <source>Prog. Retin. Eye Res.</source><volume>20</volume>, <fpage>175</fpage>&#8211;<lpage>208</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1350-9462(00)00027-6</pub-id>, PMID: <pub-id pub-id-type="pmid">11173251</pub-id></mixed-citation></ref><ref id="ref144"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>D.-Y.</given-names></name><name name-style="western"><surname>Cringle</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Su</surname><given-names>E.-N.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>P. K.</given-names></name></person-group> (<year>2000</year>). <article-title>Intraretinal oxygen levels before and after photoreceptor loss in the RCS rat</article-title>. <source>Invest. Ophthalmol. Vis. Sci.</source><volume>41</volume>, <fpage>3999</fpage>&#8211;<lpage>4006</lpage>, PMID: <pub-id pub-id-type="pmid">11053305</pub-id></mixed-citation></ref><ref id="ref145"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zandi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nakao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chun</surname><given-names>K. H.</given-names></name><name name-style="western"><surname>Fiorina</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>D.</given-names></name><name name-style="western"><surname>Arita</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>ROCK-isoform-specific polarization of macrophages associated with age-related macular degeneration</article-title>. <source>Cell Rep.</source><volume>10</volume>, <fpage>1173</fpage>&#8211;<lpage>1186</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2015.01.050</pub-id>, PMID: <pub-id pub-id-type="pmid">25704819</pub-id><pub-id pub-id-type="pmcid">PMC5219927</pub-id></mixed-citation></ref><ref id="ref146"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zanke</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hawken</surname><given-names>S.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chow</surname><given-names>D.</given-names></name></person-group> (<year>2010</year>). <article-title>A genetic approach to stratification of risk for age-related macular degeneration</article-title>. <source>Can. J. Ophthalmol.</source><volume>45</volume>, <fpage>22</fpage>&#8211;<lpage>27</lpage>. doi: <pub-id pub-id-type="doi">10.3129/i09-209</pub-id><pub-id pub-id-type="pmid">20130705</pub-id></mixed-citation></ref><ref id="ref147"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeiss</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>E. A.</given-names></name></person-group> (<year>2004</year>). <article-title>Proliferation of microglia, but not photoreceptors, in the outer nuclear layer of the rd-1 mouse</article-title>. <source>Invest. Ophthalmol. Vis. Sci.</source><volume>45</volume>, <fpage>971</fpage>&#8211;<lpage>976</lpage>. doi: <pub-id pub-id-type="doi">10.1167/iovs.03-0301</pub-id><pub-id pub-id-type="pmid">14985319</pub-id></mixed-citation></ref><ref id="ref148"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X. A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L. P.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Tso</surname><given-names>M. O. M.</given-names></name></person-group> (<year>2005</year>). <article-title>Identification of sequential events and factors associated with microglial activation, migration, and cytotoxicity in retinal degeneration in rd mice</article-title>. <source>Invest. Ophthalmol. Vis. Sci.</source><volume>46</volume>, <fpage>2992</fpage>&#8211;<lpage>2999</lpage>. doi: <pub-id pub-id-type="doi">10.1167/iovs.05-0118</pub-id><pub-id pub-id-type="pmid">16043876</pub-id></mixed-citation></ref><ref id="ref149"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hanke-Gogokhia</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gerstner</surname><given-names>C. D.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Mistrafficking of prenylated proteins causes retinitis pigmentosa 2</article-title>. <source>FASEB J.</source><volume>29</volume>, <fpage>932</fpage>&#8211;<lpage>942</lpage>. doi: <pub-id pub-id-type="doi">10.1096/fj.14-257915</pub-id><pub-id pub-id-type="pmid">25422369</pub-id><pub-id pub-id-type="pmcid">PMC4422365</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>